Characterization of potential anti-diabetic related-proteins from Pleurotus Pulmonarius (Fr.) Quel. (grey oyster mushroom) / Nurul Azwa Abd Wahab by Nurul Azwa , Abd Wahab
 ii 
ABSTRACT 
 
 Diabetes mellitus is a chronic metabolic disorder due to carbohydrate, fat and 
protein metabolism disturbances, resulting from defects of insulin secretion (Type 1), 
increased cellular resistance to insulin (Type 2) or both. Diabetes is characterized by an 
abnormally high level of blood glucose (hyperglycemia) that leads to serious damage of 
the body organs. World Health Organization estimates almost 220 million people 
worldwide diagnosed by diabetes and likely to be doubled by the year 2030. 
Furthermore, untreated diabetes will contribute to complications such as heart disease, 
stroke, hypertension, nervous system disease and amputation. Currently, researchers 
approach for an alternative therapeutic for combating the most prevalent diabetes, 
which is type 2 diabetes, by delaying the absorption of carbohydrates/glucose through 
inhibition of carbohydrate hydrolysing enzymes; α-amylase and α-glucosidase enzymes. 
Previous research reported that Pleurotus pulmonarius (Fr.) Quél. has a good potential 
in reduction of hyperglycemia in type 2 diabetes and ameliorates the course of 
cardiovascular-related complications. Bioactive compounds from P. pulmonarius 
sources are considered to be less toxic and free from side effects compared to synthetic 
drugs available in market such as sulfonylureas, biguanides, glinides, tolbutamide, 
troglitazone, rosigitazone and repaglinide. Besides, the production of P. pulmonarius 
has been increasing worldwide at a rapid rate due to its broad adaptability, 
aggressiveness, ease of cultivation with high yield potential and high nutritional value. 
According to Icons of Medicinal Fungi from China, the medicinal part of the oyster 
mushroom is in its basidiocarps. Hence, the present study aims to isolate and to 
characterize potentially active protein from P. pulmonarius basidiocarps. Crude 
aqueous, methanol, dichloromethane and polysaccharide extracts as well as ammonium 
sulphate precipitated protein fraction (F10-F100) from P. pulmonarius basidiocarps 
were explored. All samples were tested via Saccharomyces cerevisiae α-glucosidase 
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and porcine α-amylase inhibitory assays in vitro. Preliminary results demonstrated that 
at 25 µg/ml, F30 protein fraction inhibited α-glucosidase with 24.18% and F100 protein 
fraction inihibited α-amylase activity with 41.80%. Nevertheless, crude aqueous, 
methanol, dichloromethane, polysaccharide extracts at 25 mg/ml showed meagre 
inhibitory activities towards both assays. Selected anti-diabetic inhibitors F30 and F100 
protein fractions showed a very distinct SDS-PAGE protein bands profile, 10 (5-70 
kDa) and 9 protein bands (6-70 kDa) respectively thereby, both samples were further 
purified by RP-HPLC. Following RP-HPLC, peak 3 at 2.5 µg/ml demonstrated 25% 
inhibition towards α-glucosidase (F30) but very low inhibition for α-amylase activities 
at 6.25 µg/ml with only 2.84% (F100). Characterization of peak 3 protein from F30 
protein fraction using MALDI-TOF/TOF mass spectrometry identified four different 
proteins, which could be involved in the regulation of blood glucose level via various 
mechanisms. This study revealed the presence of several anti-diabetic related proteins 
such as profilin-like protein (in-solution MALDI-TOF/TOF MS), glyceraldehyde-3-
phosphate dehydrogenase-like protein, trehalose phosphorylase-like protein and 
catalase-like protein (in-gel MALDI-TOF/TOF MS), thus suggests that the basidiocarps 
of P. pulmonarius has high potential in lowering blood glucose level, reduce insulin 
resistance and the risk of diabetic-related complications. 
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ABSTRAK 
 
 Diabetes mellitus (kencing manis) adalah masalah metabolik kronik yang 
disebabkan oleh gangguan metabolisme karbohidrat, lemak dan protein, terhasil akibat 
daripada kecacatan rembesan insulin (Jenis 1), peningkatan rintangan sel terhadap 
insulin (jenis 2) atau kedua-duanya. Diabetes dicirikan oleh paras tinggi glukosa darah 
(hiperglisemia) yang luar biasa dan membawa kepada kerosakan yang serius kepada 
organ badan. ‘World Health Organization’ menganggarkan hampir 220 juta orang di 
seluruh dunia disahkan menghidapi kencing manis dan jumlah ini berganda menjelang 
tahun 2030. Tambahan pula, kencing manis yang tidak dirawat akan menyumbang 
kepada komplikasi seperti penyakit jantung, strok, darah tinggi, penyakit sistem saraf 
dan amputasi. Pada masa ini, penyelidik mendekati terapi alternatif untuk memerangi 
diabetes yang paling lazim, iaitu diabetes jenis 2, dengan melengahkan penyerapan 
karbohidrat/glukosa melalui perencatan enzim pencernaan karbohidrat; α-amilase dan 
α-glucosidase. Kajian sebelum ini melaporkan bahawa Pleurotus pulmonarius (Fr.) 
Quel. mempunyai potensi yang besar dalam mengurangkan hiperglisemia dalam 
diabetes jenis 2 serta mencegah komplikasi yang berkaitan dengan kardiovaskular. 
Sebatian bioaktif daripada P. pulmonarius dianggap kurang toksik dan bebas daripada 
kesan sampingan berbanding dengan ubat-ubatan sintetik yang terdapat di pasaran 
seperti sulfonylureas, biguanid, glinides, tolbutamide, troglitazone, rosigitazone dan 
repaglinide. Selain itu, pengeluaran P. pulmonarius telah meningkat di seluruh dunia 
pada kadar yang pesat disebabkan oleh penyesuaian yang luas, agresif, kemudahan 
penanaman dengan hasil yang berpotensi tinggi dan nilai pemakanan yang tinggi. 
Menurut ‘Icons of Medicinal Fungi from China’, bahagian perubatan cendawan tiram 
ialah basidiokap. Oleh itu, kajian ini bertujuan untuk mengasingkan, mengenal pasti dan 
mencirikan protein daripada basidiokap P. pulmonarius. Ekstrak air mentah, metanol, 
diklorometana dan polisakarida serta fraksi protein melalui pemendakan ammonium 
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sulfat (F10-F100) daripada basidiokap P. pulmonarius telah dikaji. Semua sampel telah 
diuji secara in vitro melalui ujian perencatan enzim α-glucosidase dari Saccharomyces 
cerevisiae dan α-amilase dari khinzir. Keputusan awal menunjukkan bahawa pada 25 
μg/ml, fraksi protein F30 merencatkan α-glucosidase sebanyak 24.18% dan fraksi 
protein F100 merencatkan aktiviti α-amilase sebanyak 41.80%. Walau bagaimanapun, 
ekstrak air mentah, metanol, diklorometana dan polisakarida pada 25 mg/ml 
menunjukkan aktiviti perencatan yang rendah terhadap kedua-dua ujian. Fraksi protein, 
(F30 dan F100) menunjukkan profil jalur protein SDS-PAGE yang berbeza masing-
masing dengan 10 (5-70 kDa) dan 9 jalur protein (6-70 kDa) dan dipilih untuk analisis 
RP-HPLC. Melalui penulenan menggunakan RP-HPLC, puncak 3 pada 2.5 μg/ml 
merencat aktiviti α-glucosidase (F30) dengan 25% peratus sedangkan aktiviti 
perencatan α-amilase pada 6.25 μg/ml adalah sangat rendah dengan hanya 2.84% 
(F100). Pencirian puncak 3 protein dari F30 fraksi protein menggunakan MALDI-
TOF/TOF MS menunjukkan kehadiran empat protein berbeza yang mungkin terlibat 
dalam merendahkan tahap glukosa darah melalui pelbagai mekanisma. Kajian ini 
menunjukkan kehadiran beberapa protein yang berkaitan dengan anti-diabetik seperti 
‘profilin-like protein’ (in-solution MALDI-TOF/TOF MS), ‘glyceraldehyde-3-fosfat 
dehidrogenase-like protein’, ‘trehalose phosphorylase-like protein’ dan ‘catalase-like 
protein’ (in-gel MALDI-TOF/TOF MS) dan mencadangkan bahawa basidiokap P. 
pulmonarius mempunyai potensi yang tinggi dalam merendahkan tahap glukosa darah, 
mengurangkan rintangan insulin dan risiko komplikasi yang berkaitan dengan kencing 
manis. 
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1.0 INTRODUCTION 
 Diabetes mellitus (DM) is a chronic metabolic disorder in the endocrine system 
resulting from defects of insulin secretion (Type 1), increased cellular resistance to 
insulin (Type 2) or both. A consequence of this is characterized by an abnormally high 
level of blood glucose or known as hyperglycemia that leads to serious damage to many    
body organs. Without sufficient insulin available, body tissues, in particular, the liver, 
muscle and adipose tissues fail to take up and utilize glucose from the blood circulation. 
Although genetic is a main factor in the development DM, it is possible to modify DM 
via lifestyle and food diet in combating the disease (Okada, 2011).  
 DM is rapidly increasing in the whole world and currently become the third 
“killer” of human health. The prevalence of type 2 DM has been estimated to increase 
from 150 million, to 225 million by the end of the decade and is expected to increase to 
300 million by 2025 (Maggi et al., 2013). Uncontrolled DM disease leads to the 
development of both acute and long-term chronic complications such as retinopathy, 
neuropathy, amputation, organ dysfunction involving the eyes, kidneys, nervous, heart 
and damage of vascular systems thereby increase the risk of cardiovascular disease 
(Genuth et al., 2003). Untreated complications resulted from this disease can lead to 
death (Ortiz et al., 2010). 
 Currently, there are many kinds of anti-diabetic medicines that are available in 
the market such as sulfonylureas, biguanides, glinides, tolbutamide, troglitazone, 
rosigitazone and repaglinide. However, most of them are too toxic, costly, and they give 
rise to negative effects to the patient and significantly fail to alter the course of diabetic 
complications. Furthermore, the major focus of current anti-diabetic research is the 
development of anti-hyperglycemic agents that are safe and free of negative side effects 
such as nausea, diarrhoea, liver problems and weight gain (Malviya et al., 2010).  
 Recently, many researchers are working on an alternative therapeutic approach 
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for combating DM by decreasing postprandial hyperglycemia via delaying the 
absorption of carbohydrates/glucose through the inhibition of carbohydrate hydrolysing 
enzymes; α-amylase and α-glucosidase enzymes in the digestive tract using compound 
from natural sources such as polysaccharides, proteins, steroids terpenoids and alkaloids 
(Etxeberria et al., 2012). 
 Bioactive proteins can be isolated via proteomics study which is an excellent 
tool in profiling, discovering, and identifying proteins produced in response to a 
changing cellular environment (Aebersold & Mann, 2003). Proteome analyses involve a 
wide variety of methods that include protein purification such as ammonium sulphate 
precipitation, separation using high performance liquid chromatography (HPLC), SDS-
PAGE and identification using MALDI-TOF/TOF mass spectrometry. 
 Many mushroom species such as Agaricus bisporus, Agaricus subrufescens, 
Grifola frondosa, Pleurotus ostreatus, and Cordyceps sinensis are found to be effective 
for controlling the blood glucose levels and modify the course of diabetic complications 
(Barra et al., 2012). Pleurotus pulmonarius (grey oyster mushroom) is an excellent 
candidate mushroom claimed to have anti-diabetic properties. Bioactive compound 
from mushrooms are considered to be less toxic and free from side effects compared to 
synthetic drugs. Moreover, it contains numerous bioactive compounds including 
polysaccharides, protein and dietary fibres isolated whether from the whole mushroom 
or mycelia. These compounds showed potential as antihyperglycemic agents (Khan & 
Tania, 2012). 
  In addition, the production of P. pulmonarius has been increasing worldwide at 
a rapid rate due to its broad adaptability, aggressiveness, ease of cultivation with high 
yield and high nutritional value. Furthermore, it can be cultivated within a wide range of 
temperatures on different natural resources and agricultural wastes (Tan & Wahab, 
1997). Previous research reported that P. pulmonarius has a good potential in reduction 
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of hyperglycemia in type 2 DM and ameliorate the course of cardiovascular-related 
complications (Kanagasabapathy et al., 2012). Meanwhile, the aqueous extract of P. 
pulmonarius basidiocarp also contains vitamin B1, B2, and C and it can also reduce the 
blood cholesterol level (Pramanik, 2005).  
 To date, there are no reports on the active protein(s) with anti-diabetic properties 
isolated from the P. pulmonarius basidiocarps.  
Hence, the objectives of this research were focused on: 
1. To prepare the organic, aqueous and protein extracts from basidiocarps of P. 
pulmonarius. 
2. To evaluate the anti-diabetic activities in vitro of the prepared extracts. 
3. To identify and characterise the peptides isolated from the bioactive extract by 
MALDI TOF/TOF mass spectrometer. 
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2.0 LITERATURE REVIEW 
2.1 Diabetes Mellitus 
 Diabetes mellitus (DM) is a group of metabolic disease characterized by 
hyperglycemia resulting from defects of insulin secretion by pancreas, increased cellular 
resistance to insulin or both. In the human normal system, when foods containing starch 
or simple sugars are digested and absorbed into the blood through the intestines, insulin 
helps the body to store these nutrients throughout the body for later use as a source of 
energy. Therefore, it will keep removing extra glucose from the blood, causing the 
blood sugar level to decrease and always maintained at normal levels (Shobana et al., 
2009). DM appears due to improper homeostasis regulation of carbohydrate and lipid 
metabolism by insulin. As a consequence, abnormally elevated levels of glucose 
accumulated in the blood occurs which in turn leads to serious damage to many of the 
body’s systems, especially the nerves and blood vessels (Nagappa et al., 2003; Li et al., 
2012b).  
 Nowadays, DM is becoming a dangerous threat to human health all over the 
world. It is a heterogeneous disease which is caused by genetic and environmental 
factors as well as obesity and lack of exercise (McCue et al., 2005; Smith et al., 2012). 
Although genetic factors are important in the development of type 2 DM, it is possible 
to modify them to prevent the disease (Sanz et al., 2010). People in high-risk groups are 
those who are obese, having a history of giving birth to big baby (weighing more than 4 
kg), history of gestational diabetes, having a family history of type 2 DM, or those 
belong to high-risk ethnic groups due to their lifestyle and tradition such African 
American, native American, Hispanic, Pacific Islanders. Moreover, smoking and 
alcohol drinking are also potential cause of the disease (Risch et al., 2002).  
 Besides, diabetes will be the fifth leading cause of death in the world by the year 
2030 and becomes the most challenging health problems in the 21st century (Mimino, 
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2011). According to the statistics of International Diabetes Federation (IDF), two 
individuals develop diabetes every 10 seconds all over the world, and two individuals 
die of diabetes-related disease every 10 seconds worldwide (World Diabetes Media Kit: 
every 10 seconds 1 person dies of diabetes, 2007 ). 
 The IDF also estimates at least 336 million people worldwide suffered from 
diabetes in 2011 and the number has been expected to increase to a staggering 552 
million by 2030. That concludes one in ten adult will have diabetes and the number of 
people with type 2 DM is increasing in every country (Shaw et al., 2010; Kwon, 2012). 
Moreover, the death cases were estimated to be 3.96 million of diabetic people in the 
age group 20–79 years in 2010 (Roglic & Unwin, 2010). The number of death of 
diabetic people was increased in the year 2011 for at least 4.6 million deaths worldwide 
(Colagiuri, 2010; Nickerson & Dutta, 2012). Hence, the statistic was greater than the 
global mortality for hypertension, AIDS, and tuberculosis (Hu, 2011).  
 Meanwhile, increasing number of diabetic cases gives a negative impact to low- 
and middle-income countries because it imposes economic burden on national health 
care system. People with diabetes indeed have more outpatient visits, need more 
medications, have a higher probability of being hospitalized, and are more likely to 
require emergency and long-term care compared to healthy people (Zhang et al., 2010). 
In 2011, at least US$465 billion dollars have been spent which constitutes about 11% of 
the total health expenditure in adults (Oputa & Chinenye, 2012).  
 Nevertheless, untreated hyperglycemia (type 1 and type 2 DM) can also lead to 
the development of both acute and long term chronic complications such as retinopathy, 
neuropathy, amputation, renal dysfunction, tissue damage and failure of different organs 
such as eyes, kidneys, nerve, heart and vascular systems (Weiss & Sumpio, 2006; 
Kowalska, 2007; Winkley et al., 2012). Besides, chronic hyperglycemia is known to 
damage almost all cell types in the body and also increase the risk of cardiovascular 
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disease (Li et al., 2012b). Both experimental and clinical studies also suggest that there 
are a close link between hyperglycemia and diabetic complications which cause a high 
mortality and morbidity (Rabbani et al., 2009). Furthermore, without any cure and 
medical emphasis of this chronic disease will end up with many diabetes-related disease 
and untreatable complications such as coronary heart disease (Gossain & Aldasouqi, 
2010). Therefore, early diagnosis and a healthy lifestyle are pivotal choice to avert risk 
of DM (Yates et al., 2012). 
 Up until now, other than insulin treatment, there are many kind of anti-diabetic 
medicines available to control and treat diabetes and its complications mainly depend 
on the bioactive compound. However until now, there has never been a report saying 
that someone had totally recovered from DM (Li et al., 2004). Although currently 
various oral anti-diabetic agents are available on the market such as phenformin, 
troglitazone, biguanides, rosigitazone, glinides, tolbutamide, repaglinide and 
sulfonylureas, which are widely used drugs for diabetic treatment, they produce 
negative side-effects, fail to alter the course of diabetic complications as well as affects 
other body metabolisms (Patel et al., 2012).  
 The definitions and categories of DM used in this document are based on the 
most recent classifications reported by the American Diabetes Association. There are 
three main types of DM; type 1 DM, type 2 DM and gestational diabetes. Other forms 
of diabetes which were caused by a single gene mutation and damaging the quality of 
insulin were seldom found (Velho & Froguel, 1997). 
 
2.1.1 Type 1 Diabetes Mellitus 
 Type 1 DM is also known as insulin dependent diabetes mellitus (IDDM) or 
juvenile diabetes. This type occurs as a result of the body’s failure to produce insulin 
due to destructive lesions of insulin producing β-cells of the islets of Langerhans 
 7 
located in the pancreas and usually progresses to the stage of absolute insulin deficiency 
(Kobayashi, 1994; Pozzilli & Buzzetti, 2007).  
 Commonly, type I diabetes occurs in children or adults subjects with acute onset 
thus it was termed as “juvenile diabetes” (Imagawa et al., 2000). People with type 1 DM 
depend on exogenous insulin by daily intake of insulin injections to stay alive and they 
also have a risk for ketoacidosis. Type 1 DM develops approximately 5–10% of 
diagnosed diabetes cases in all countries but the incidence is rapidly increasing 40% 
higher in the year 2010 compared to 1999 (Sierra, 2009). Only half a million people 
have type 1 DM worldwide, and only 78 000 children develop the disease every year 
(Oputa & Chinenye, 2012). Until now, there are no specific or identified agent capable 
to control or prevent this type of diabetes (Atkinson & Eisenbarth, 2001). 
 
2.1.2 Type 2 Diabetes Mellitus 
 Type 2 DM is also known as non-insulin dependent diabetes mellitus (NIDDM). 
NIDDM is far more common because it accounts for 90 to 95% of all diagnosed 
diabetes cases. This type of diabetes is one of the major public health challenges of the 
21st century (Hussain et al., 2007; Oputa & Chinenye, 2012).  
 Type 2 DM occurs when body’s cells fail to use insulin properly (insulin 
resistance) in peripheral tissues such as muscle, liver and adipose. Among individuals 
suffering type 2 DM, their disease factor can be attributed to environmental exposure 
and genetics from family member diagnosed of diabetes (Eriksson & Lindstrom, 2001). 
Typically, type 2 DM develops after middle age but may occur in younger people and it 
is associated with obesity, age, and physical inactivity (Rosenbloom et al., 1999). Type 
2 DM was unheard of in children but recently it makes up 40-50% of cases with the rest 
being type 1 DM (Davis & Christoffel, 1994).  
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2.1.3 Gestational Diabetes Mellitus 
 The third type of diabetes is gestational diabetes (GDM) which develops in 
pregnant women who have never had diabetes before but have a high blood glucose 
level during pregnancy (Zhang & Ning, 2011). GDM develops in only a small 
proportion of pregnant women (3–5%) (Ben-Haroush et al., 2004). 
 Indeed, women with GDM are at high risk for having or developing diabetes 
after pregnancy. This was proven as almost 50% cases of GDM may end up as type 2 
DM. Thus, GDM requires careful medical supervision throughout the pregnancy 
(Buchanan & Xiang, 2005; Oputa & Chinenye, 2012).  
 
2.2. Treatment and Management of Type 2 Diabetes Mellitus 
 Admittedly, type 2 DM is the most prevalent form of the disease, which 
diagnosed is increasing rapidly and can remain undiagnosed for many years. The 
number of patients with diabetes disease-related complications such as heart disease, 
stroke, hypertension, nervous system disease and amputation are also increasing 
unabated (Zimmet, 2003). Type 2 DM occurs when the body resistance to natural 
insulin hormone produced from the pancreas gland, essentially ignoring its insulin 
production. Insulin is continuously being secreted but the body does not respond to the 
effects of natural hormonal insulin as it should function. Insulin resistance is first 
demonstrated in skeletal muscle, in which concentrations of insulin are necessary to 
allow glucose to enter the cells (Weyer et al., 2000).  
 Nevertheless, onset of type 2 DM is difficult to detect because in the early 
stages, there are no symptoms shown. It will be discovered only when blood glucose 
levels exceed the "renal threshold" where glucose appears in the urine by medical tests. 
At this stage, the symptom of diabetes will nascent which are constant thirst 
(polydipsia), excessive excretion of urine (polyuria), immediate weight loss, constant 
 9 
hunger, blurred vision, itchy skin, fatigue and slowly cuts healing (García, 2005). 
 As a consequences, untreated DM in a long term can damage human health and 
can increase the risk of diabetes related-disease such as heart disease, stroke, kidney 
failure, nerve damage and blindness. The risk of diabetic complications usually begins 
as early as in the pre-diabetic phase. Generally, the injurious effects of hyperglycemia 
are separated into macrovascular complications (coronary artery disease, peripheral 
arterial disease, and stroke) and microvascular complications (diabetic nephropathy, 
neuropathy, and retinopathy) (Fowler, 2008).  
 Close to 50% of death that due to diabetes resulted from cardiovascular disease 
as well as heart disease and stroke and approximately 2% of diabetic patients become 
blind. Diabetic retinopathy can cause blindness among diabetic patient because of a 
long-term accumulated damage to the small blood vessels in the retina. Therefore, early 
treatment to avert the disease and its complications is a key issue because of the 
increasing huge premature morbidity, mortality and economic burdens (Zimmet, 2001).  
 Currently, medical researchers worldwide emphasize that a combination of 
insulin treatment, oral anti-hyperglycemic drugs, physical exercise, losing excess 
weight and healthy diet are effectively used to control and lower blood glucose to a 
near-normal glucose level (Sanz et al., 2010). Indeed, in the management of type 2 DM, 
it is very important to achieve blood glucose level as close as possible to normal 
without resulting in either chronically high (hyperglycemia) or dangerously low blood 
glucose levels (hypoglycemia). Both can cause severe disease complications 
(Mooradian & Thurman, 1999).  
 Despite of being the mainstay treatment to diabetic patient, insulin still has its 
shortcomings. The main drawback of this treatment is it must be given only by 
injection. Moreover, insulin treatment can cause up to 4 kg increase in body weight and 
risk of mild to severe hypoglycemia with increasing durations of the treatment 
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(Swinnen et al., 2009). Besides, majority of patients need multiple therapies correlated 
with insulin to attain normal glycemic target levels in the longer term (Turner, 1999). 
Hence, the search for active oral anti-hyperglycemic drugs was demanded not only 
because of its effectiveness but also because of each drug has unique mechanism of 
action (Inzucchi, 2002). 
 In year 2006, there are five major classes of oral anti-hyperglycemic agents in 
the market. One of the most commonly used drug is metformin which reduces the 
amount of glucose production by the liver (hepatic glucose) and improving the way 
glucose is used by muscles. It is therefore considered as insulin sensitizer. Intake of 
metformin is associated with weight loss or no weight gain and has a lower risk of 
hypoglycemia. Meanwhile, sulfonylureas are also commonly used because it helps 
stimulate pancreas to increase insulin release from pancreatic islets. Second-generation 
sulfonylureas, such as glyburide, glipizide, and glimepride, are safer, potent and lesser 
drug interactions than first-generation sulfonylureas such as chlorpropamide, 
tolazamide, and tolbutamide (Riddle, 2000). Prandial-glucose regulators for example, 
repaglinide also encourage pancreas to produce more insulin (Shoelson, 1995). 
 Other mostly consumed oral anti-hyperglycemic agent is α-glucosidase 
inhibitors such as acarbose and voglibose which were introduced in 1996. It is a 
complex oligosaccharide which reversibly inhibits α-glucosidase, the final enzymes 
which cleaves more complex carbohydrates into sugars in the brush border of small 
intestinal mucosa. This drug lowers blood glucose by slowing the breakdown of some 
ingested carbohydrates into glucose thus maintain the blood glucose level (Wehmeier & 
Piepersberg, 2004). 
 Hence, in order to search for safer new drug in preventing and treatment of type 
2 DM and complications, more research is needed in this field. This is due to the 
existing synthetic drugs have several limitations in term of tolerability and significant 
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mechanism-based side effect which prompt patients to stop taking these anti-diabetic 
medications. Major drawbacks of oral anti-diabetic agents are most of them may cause 
weight gain, abnormal colon function, give metallic taste, nausea, and the severity of 
gastrointestinal disturbances such as frequent diarrhoea, colon bloating and flatulence 
(Glucotrol, 2001; Fisman et al., 2004). The most bothersome side effects of synthetic 
drugs is on postprandial hyperglycemia (DeFronzo, 1999). 
 For diabetes control, rather than the synthetic drugs, many agents from the plant 
origin such as proteins and polysaccharide have been explored and used particularly for 
the treatment of type 2 DM (Arayne et al., 2007). However, a number of herbal and 
plants origin medicines have already been used since ancient times but yet to be 
commercially formulated as modern medicines (Grover et al., 2002). Therefore, new or 
alternative therapies using other natural sources for new drugs as no drug which are 
definitely considered to be less toxic and free from harmful side effects compared to 
synthetic drugs need to be further researched (Pari & Umamaheswari, 2000). 
 
2.3 Blood Glucose Homeostasis  
 Carbohydrate taken by human or mammals from various dietary sources is a 
primary source of glucose. Since glucose is the main energy for the body, it is required 
to be continuously supplied to ensure all body cells function properly. The glucose level 
in bloodstream fluctuates because it depends on the body needs. Blood glucose 
homeostasis is maintained by a balance between glucose entry into the blood circulation 
and its removal from the blood circulation (Postic et al., 2004). The diet, type and 
amount of carbohydrate, the rate of carbohydrates digestion, absorption of 
carbohydrates, breakdown of glycogen as well as the activity of the hepatic 
gluconeogenesis and glycogenolysis process influence glucose entry into the 
circulation. Nevertheless, insulin and glucagon are hormones that have a great 
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responsibility to precisely regulate the amount of glucose in the bloodstream. These 
hormones drain directly into the liver.   
 Insulin is an important hormone, where it regulates the blood glucose level to 
the normal level. Insulin producing beta cells, clumps together to form the "islets of 
Langerhans" which are found in pancreas gland (Grover et al., 2002). The pancreatic 
"islets of Langerhans" are the sites for the production of insulin and glucagon. Hence, 
the pancreas plays a primary role in the metabolism of glucose either to secrete the 
insulin or glucagon hormones. 
 Commonly, insulin will be released from pancreas mostly when the level of 
postprandial blood glucose is high. When glucose is abundant, the pancreatic beta cells 
will stimulate secretion of insulin into the bloodstream (Reaven, 1988). In order to 
maintain blood glucose level, insulin will triggers the cells to use glucose in protein 
synthesis. Insulin promotes glucose storage and stimulates cells to breakdown glucose 
(glycolysis) by releasing it as an energy in the form of ATP and citric acid cycle (Yakar 
et al., 2004). Meanwhile, insulin also ease the entry of glucose into the adipose and 
muscle tissues and store it as glycogen for short-term energy storage whereas for long-
term storage, adipose tissue will store glucose as fat (Bekele, 2008). As a result, the 
glucose level in the blood decreases. On the other hand, insulin inhibits the production 
and release of glucose from the liver (gluconeogenesis and glycogenolysis). Likewise, 
insulin inhibit glucagon production. 
 Otherwise, glucagon hormone will be released by pancreas when blood glucose 
level is scarce and insulin levels are low. Generally, glucagon stimulates the liver to 
produce glucose and releases it into the bloodstream. However, when blood glucose and 
insulin levels are high after a meal, glucagon levels will immediately drop, and the liver 
stores excess glucose for later use. The actions of glucagon and insulin work in an 
opposing manner so as to regulate and maintain a rigid control on glucose 
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concentrations in the blood (Aguilar-Parada et al., 1969). 
 When the blood glucose levels are diminished, in order to raise the blood 
glucose level approximately between 70 to 110 mg/dl, glucagon will be released. 
Glucagon raises blood sugar levels by stimulating the mobilization of glycogen stores in 
the liver, release energy and providing a rapid burst of glucose. Furthermore, glucagon 
stimulates both gluconeogenesis and glycogenolysis thereby releases blood glucose into 
the blood circulation. Conversely, it inhibits glycogenesis process. Glucagon also helps 
to stimulate glucose production by favouring the hepatic uptake of amino acids, the 
carbon skeletons of which are used to make glucose. Moreover, glucagon acts to trigger 
the body to switch and use resources other than glucose, such as fat and protein 
(Cummings, 2006). 
 In patients with diabetes, a blood glucose level remains high regardless of the 
level of insulin since its function or the production of insulin has been stopped. This 
differentiates between type 1 and type 2 DM patients. For type 2 DM, the blood glucose 
concentration remains increased despite the presence of normal to high insulin 
concentration in the bloodstream and this is referred as insulin resistance. 
 
2.4 Mechanisms to Lower Blood Glucose Level 
 Carbohydrates are the major constituents of human diet and polysaccharides are 
one of the main components of carbohydrates that mainly play a role in the energy 
supply (Nickavar & Yousefian, 2009). In order to be absorbed in the duodenum and 
upper jejunum as energy, the dietary carbohydrates should first be hydrolysed to 
monosaccharides by α-glucosidase enzyme in small intestinal brush-border, since only 
monosaccharides can be absorbed by intestinal lumen (Kwon et al., 2006a).  
 As well as dietary polysaccharides, it first are hydrolyzed in the gastrointestinal 
tract by the α-amylase enzyme to produce oligosaccharides and disaccharides. The 
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resulting oligosaccharides and disaccharides are further hydrolyzed by α-glucosidase 
enzymes to further produce glucose and other monosaccharides such as fructose and 
galactose before being absorbed as blood glucose (Bhat et al., 2011). Glucose and other 
monosaccharides resulting from digestion of carbohydrates and polysaccharide are 
absorbed through the small intestine into the hepatic portal vein thus result in elevation 
of the postprandial blood glucose level. This proves that the postprandial hyperglycemia 
strongly depends on the amount of absorbed monosaccharides and the rate of digestion 
into small intestines.  
 Indeed, in the effort to control postprandial hyperglycemia, many researchers 
have focused on the starting process of carbohydrate metabolism, particularly in glucose 
releasing and transport across the intestinal brush border membrane down to the blood 
stream (Tiwari & Madhusudanarao, 2002). They found that the inhibition of 
carbohydrate hydrolysing enzymes, α-amylase and α-glucosidase delaying the 
breakdown and absorption of carbohydrates (sucrose, dextrins, maltose, and starch) 
from the digestive tract can reduce postprandial hyperglycemia. However, the treatment 
of type 2 DM is complicated because of various factors affecting the disease occurrence 
and one of it is elevated postprandial hyperglycemia (Gin & Rigalleau, 2000). Good 
glycemic control can reduce postprandial hyperglycemia and decreases the risk for both 
type 2 DM and its complication. Thus, these enzyme inhibitor drugs have been one of 
the major focus nowadays (Jayasri et al., 2009). 
 
2.5 Alpha Glucosidase and Alpha Amylase Enzymes Inhibitors 
 Alpha glucosidase which is one of the carbohydrate metabolism enzymes, is 
responsible to degrade complete carbohydrates into monosaccharides. The released non-
reducing sugar is easily absorbed through intestines into the bloodstream (Shobana et 
al., 2009). Alpha glucosidase inhibitors acts as a competitive inhibitors of glucosidases 
which are located in the brush border of epithelial cells, mainly in the upper half of the 
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small intestine (Moller, 2001; Bailey, 2004). This process occur when the α-glucosidase 
inhibitors bind reversibly in a dose-dependent manner to the oligosaccharide binding 
site of α-glucosidase enzymes thereby delay the degradation of polysaccharides and 
starch to glucose (Franco et al., 2002). Hence, this enzyme inhibitor helps in slowing 
down food digestion in the gut thereby reduce peak blood glucose concentrations. 
Importantly, enzyme inhibitors function without increasing insulin secretion, do not 
cause hypoglycemia or weight gain and may also act as effective anti-obesity agents 
(Kotowaroo et al., 2006). 
  Another inhibitor related to α-glucosidase inhibitor is α-amylase inhibitor that 
also offer an alternative therapeutic approach in reducing the postprandial 
hyperglycemia. In order to ultimately slowing glucose breakdown from starch, α-
amylase enzyme that cleaves at internal bonds of large polysaccharides is inhibited (Da 
Silva Pinto et al., 2008). This α-amylase inhibitor inhibits the action of α-amylase 
enzyme leading to retard the liberation of maltose from starch hydrolysis which shows 
beneficial effects on glucose level control in diabetic patients (Notkins, 2002).  
 It has been recently reported that therapeutic approach to delay the absorption of 
carbohydrates or glucose into gastrointestinal after meal to prevent postprandial 
hyperglycemia is now increasingly important as alternative to treat type 2 DM 
(Ademiluyi & Oboh, 2011). Since 90% of the diabetic patients are suffering from type 2 
DM, it is important that dietary α-glucosidase and α-amylase inhibitors are featured and 
be emphasized upon the production of new drug (Ranilla et al., 2010). A safe drug that 
reduce postprandial hyperglycemia by suppressing the absorption of carbohydrate are 
effective in type 2 DM prevention and treatment. The purification and characterization 
of the new inhibitor of carbohydrate hydrolysing enzymes may provide an insight into 
the reasons of development of alternative anti-diabetic drugs. Besides, a research 
regarding glucosidase inhibitors is important and become an important biochemical 
 16 
tools for studying the mechanism of enzyme-catalyzed glycoside, oligosaccharide 
structure, medicinal chemistry and researchers can understand the cause of diabetes 
intensively (Chen et al., 2004).  
 These types of observations led to the hypothesis that drugs act on the 
gastrointestinal tract to interfere with carbohydrate digestion might be useful agents in 
the treatment of diabetes, reduced risk of cardiovascular disease and hypertension 
(Lebovitz, 1997; Van de Laar et al., 2007). Although powerful synthetic α-glucosidase 
and α-amylase inhibitors such as acarbose, miglitol, voglibose and emiglitate for the 
treatment of type 2 DM are widely used nowadays, it has been reported that it can cause 
several harmful side effects such as hepatic disorders, cause abdominal pain, flatulence, 
diarrhoea and may increase the incidence of renal tumours, hepatic injury and acute 
hepatitis (Singh et al., 2008). This results from the undigested carbohydrate available in 
the colon which is then fermented into short-chain fatty acids and releasing gas (Nolte 
& Karam, 2004). In addition, there is no report found about the long-term effectiveness 
of commercial inhibitors reducing chronic complication (Cheng & Fantus, 2005). The 
effect of drugs from natural sources has not yet been reported. Due to this, it is 
important to identify natural new α-glucosidase and α-amylase inhibitors as alternative 
to reduce diabetes cases. 
 Since 2001, several safer natural α-amylase and α-glucosidase inhibitors 
compounds such as alkaloids, triterpene, acids, phytosterol, myoinositol, flavonoids, 
anthraquinones, anthrones, xanthones, anthocyanin and others were isolated from plants 
that contributes to management of hyperglycemia linked to type 2 DM (Matsui et al., 
2001; Kim et al., 2005; Da Silva Pinto et al., 2008; Benalla et al., 2010). It has been 
reported that many medicinal plant and herbal extracts have been found to inhibit the 
enzymatic activity of α-glucosidase and α-amylase (McCue & Shetty, 2004). Kobayashi 
et al., (2002) also reported screening of various plants for α-amylase inhibitory activity 
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and the resultant in vivo postprandial hyperglycemia activity. However, Kwon et al., 
(2006b) had reported that plant origin for both inhibitors with stronger activity 
attenuates the α-glucosidase enzyme but not significant inhibitor effects on α-amylase 
enzyme activity. 
 In the recent years, more researchers have moved on to venture new exciting 
candidate other than plants and herbs to help control and manage postprandial 
hyperglycemia. Natural resources such as seaweed and mushroom has now gain an 
interest of many researchers (Silva et al., 2012). As an example, Mohamed et al., (2012) 
reported that seaweed, Gymnopilus edulis showed a potent inhibitory action against 
enzyme glucosidase. Nowadays, screening of α-amylase and α-glucosidase enzymes 
inhibitors from mushroom species have received much attention throughout the world 
(Silva et al., 2012). Edible mushrooms such as Lentinus edodes, Ganoderma lucidum, 
Schizophyllum commune and Trametes versicolor are now considered to be an 
important source of nutrients and popular as non-toxic medicines (Wasser & Weis, 
1999); and therefore worth to be investigated or screen for their potential as inhibitors 
for the α-amylase and α-glucosidase enzyme. 
 
2.6 Nutritional and Medicinal Properties of Mushrooms for the Prevention of 
 Diabetes Mellitus 
 Mushrooms are defined as macrofungus with a fleshy and distinctive fruiting 
body structure, large enough to be picked by hand or to be seen with naked eyes 
(Chang, 2008; Guillamon et al., 2010). It is a popular delicacy, widely consumed as a 
human daily food for thousands of years in many countries probably due to their 
attractive taste and texture (De Silva et al., 2012). In ancient times, only the 
basidiocarps are consumed but nowadays the mycelia are also being processed and 
widely commercialized (Smith, et al., 2002; Lindequist et al., 2005; Hyde et al., 2010).  
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 Wild or cultivated mushrooms have vast prospects as natural sources of 
medicine with a high nutritional, pharmacological effect and economic values. 
Furthermore, many previous studies have confirmed that mushrooms are an important 
source of nutritional food as well as income in for many countries (Wong et al., 2001). 
Amongst the many species used in health prospect are Claviceps purpurea, Cordyceps 
sinensis, Ganoderma lucidum, Laricifomes officinalis, Lentinula edodes and Trametes 
versicolor (Molitoris, 2005). However, according to Hawksworth (2001), there are 7000 
yet undiscovered species with medicinal potential.    
 Recently, mushrooms become popular as a functional food and as a remarkable 
source for development of new drug because it contains a numerous bioactive 
compounds that have shown therapeutic benefits against the development of many 
diseases (Carbonero et al., 2008; Cheung, 2008; Lee & Hong, 2011). The most popular 
edible mushrooms include Agaricus bisporus, Pleurotus species, Lentinula edodes, 
Volvariella volvacea, Auricularia species, Flammulina velutipes, Tremella fuciformis, 
Hypsizygus marmoreus, Pholiota nameko and Grifola frondosa (Manzi et al., 2001; 
Sanchez, 2010). Hence, consumption of whole, extracts or concentrates edible 
medicinal mushroom provides nutraceutical properties and helps in prevention or 
treatment of many diseases because it contains high molecular weight compounds such 
as polysaccharides, digestible proteins and lipids as well as a number of low molecular 
weight metabolites such as lectins, lactones, terpenoids, alkaloids, sterols and phenolic 
substances (Barros et al., 2008; Chun, 2011). Mushrooms species also contains high 
amount of functional bioactive compounds, rich in minerals, proteins, fibers, 
carbohydrates and have high levels of water (Lindequist et al., 2005; Caglarirmak, 
2007; Elmastas et al., 2007; Smiderle et al., 2012).  
 Besides that, mushrooms also contain vitamins, minerals and low fat levels thus 
is excellent to be included in daily low caloric diets (Agrahar-Murugkar & 
 19 
Subbulakshmi, 2005). Mushroom has been established as a high source of minerals such 
as copper, iron, potassium, magnesium, selenium, phosphorus, manganese, sodium, 
calcium and zinc in the human diet and are very low in sodium (Román et al., 2007; 
Gençcelep et al., 2009). Furthermore, mushroom proteins is comparable to animal 
proteins, which is of particular importance to counterbalance a high consumption of 
protein animal food sources, especially in daily diets of developed countries (Okoro, 
2012). Mushroom also acts as a excellent replacement of vegetable in daily diet routine 
(Sadler, 2003). Moreover, one species can possess a high variety of bioactive 
compounds, and therefore indicates various pharmacological effects. For example is 
Ganoderma lucidum, which not only contains more than 120 different triterpenes but 
also polysaccharides, proteins and other bioactive compounds (Lindequist et al., 2005). 
 Because of the high content of various beneficial compounds, many of edible 
mushrooms have shown the ability and potential to prevent several chronic diseases 
such as anti-tumour, cardiovascular, cancer, hypertension, metabolic syndrome, 
antiviral, antibacterial, anti-parasitic and anti-diabetic (Bobek et al., 1998; De Silva et 
al., 2012) ( Table 2.1). Recently, many studies have focused on immunomodulatory and 
anti-tumour effects because mushrooms may contain a diverse array of biologically 
active metabolites (β-D-glucans) with well-known immune enhancing capabilities 
(Wasser, 2011; Wu et al., 2012). Moreover, mushrooms are important source of strong 
antioxidant and have potent free radical-scavenging activities (Ajith & Janardhanan, 
2007). Besides, mushroom helps to inhibit platelet aggregation, reduce of blood 
cholesterol concentration, prevent heart disease, and block induced liver peroxidation 
(Ghaly et al., 2011). Therefore, high production of mushrooms in a larger scale are 
important in order to meet the high demands of the global market (Guillamon et al., 
2010). 
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Table 2.1: Examples of medicinal mushrooms and their pharmacological effects 
 
Species (active compound 
identified) 
Function References 
Agaricus bisporus,  
A. brasiliensis, Trametes 
versicolor, Grifola frondosa, 
Inonotus obliquus, Lentinus 
edodes, Leucoagaricus 
americanus, Pleurotus 
ostreatus, and Sparassis crispa 
Breast cancer inhibitory activity (Petrova et 
al., 2005) 
Agaricus blazei 
(polysaccharide-protein 
complex) 
Treatment of tumour, 
hypertension, diabetes, obesity 
and hepatitis 
(Mizuno et 
al., 1999) 
Flammulina velutipes 
(flammulin, a basic simple 
protein) 
Protective against increased serum 
cholesterol level and inhibit 
tumour cells 
(Ling et al., 
1990) 
Flammulina velutipes and 
Hypsizygus marmoreus 
High anti-tumour activity, treat 
liver diseases, gastric ulcers and 
cancer prevention 
(Ikekawa, 
2001) 
Ganoderma lucidum Enhancement of lymphocyte 
proliferation and antibody 
production, producing both anti-
genotoxic and anti-tumour 
promoting activities 
(Bao et al., 
2001; 
Wasser, 
2002) 
Ganoderma lucidum 
(triterpenes) 
Anti-tumour effect (Bao et al., 
2001) 
Grifola frondosa Antiviral properties (Gu et al., 
2007) 
Inonotus obliquus  
(melanin complex) 
Antioxidant and 
genoprotective effects 
(Chihara et 
al., 1969) 
Lentinula edodes (shiitake) 
(lentinan, a β-1,3-glucan) 
Anti-tumour, increasing 
production of T-cells and 
macrophages 
(Ikekawa, 
2001; Sadler, 
2003) 
P. cornucopiae Antihypertensive activity (Hagiwara et 
al., 2005) 
P. florida Inhibited platelet aggregation and 
anti-inflammatory activities 
(Jose et al., 
2004). 
P. linteus 
 
Anti-inflammatory effect (Kim et al., 
2004) 
P. ostreatus and P. 
citrinopileatus 
Antihyperlipidaemic (Hossain et 
al., 2003; Hu 
et al., 2006a) 
P. ostreatus, Pleurotus ferulae 
and Clitocybe maxima 
Antioxidant properties (Tsai et al., 
2009) 
Phellinus rimosus, P. florida, 
P. sajor caju a.k.a P. 
pulmonarius and Ganoderma 
lucidum 
Antioxidant activity (Lakshmi et 
al., 2004) 
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Table 2.1, continued 
 
Species (active compound 
identified) 
Function References 
Piptoporus betulinus   
 
Treatment of rectal 
cancer and stomach diseases 
(Lemieszek 
et al., 
2009) 
Pleurotus ostreatus Exert anti-tumour activity 
against Hela tumour cell, 
antibacterial and antifungal 
properties 
(HaiBin et 
al., 2009; 
Hearst et 
al., 2009) 
Pleurotus tuber-regium Anti-tumor (Tao et al.,  
2006) 
Schizophyllum commune 
(polysaccharide schizophyllan) 
Anti-cancer activity (Ooi & 
Liu, 2000; 
Daba & 
Ezeronye, 
2004) 
Trametes versicolor 
(krestin and polysaccharide-peptide) 
Liver protective effect, 
antitumor and powerful 
immunostimulant and anti-
cancer agent 
(Ng, 1998; 
Ooi, 2001) 
Tremella fuciformis 
(glucuronoxylomannan) 
Anti-cancer activity and 
enhance immune functions 
(Hobbs, 
1995) 
Tricholoma giganteum The blood pressure-lowering 
action 
(Ooi, 2001) 
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 Some mushroom, especially Pleurotus genus also possess a number of bioactive 
compounds such as polysaccharides, mevinolin and other statins with hypocholestero-
laemic activities (Gunde-Cimerman & Plemenitas, 2001). There are also excellent 
producers of lovastatin, a cholesterol-lowering drug that was reported to be the best 
therapeutic agent for ameliorating hypercholesterolemia (Gunde-Cimerman & 
Plemenitas, 2001; Mattila et al., 2001; Jayakumar et al., 2006).  Pleurotus genus have 
also been proven to be a good source of essential amino acids that have several 
medicinal properties such as antioxidant activities (Badole et al., 2006). The aqueous 
extract of Pleurotus fruit body also contains vitamin B1, B2, C, D and K which can 
reduce the cholesterol level in blood (Pramanik et al., 2005). Meanwhile, the fat fraction 
in mushroom is mainly composed of unsaturated fatty acids (Mattila et al., 2001). 
 In the future, it is anticipated that mushroom have a good potential and vital in 
medicine and biotechnology field because of their unique biosynthetic capabilities and 
contain various metabolic compounds (Román et al., 2007). The ongoing research will 
explore a new generation of food originated from mushrooms due to great potential for 
the prevention or cure of disease more than in other plant species. Nevertheless, more 
research needed to be noteworthy to ensure the mushrooms species are free from 
poisonous and high heavy-metal concentrations. 
 
2.6.1 Anti-diabetic Properties of Mushrooms 
 Up to now, many researchers have shown that certain mushrooms may have 
potential to lower elevated blood sugar levels and have been targeted as potential 
hypoglycemic and anti-diabetic agents (Table 2.2). Bioactive metabolites including 
polysaccharides, protein and dietary fibres such as β-glucans have been successfully 
isolated from basidiocarps and mycelia of mushroom which markedly decrease blood 
glucose (Xiao et al., 2011). However, in order to identify the active principles for the  
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Table 2.2: Mushroom species that have medicinal properties to prevent and ameliorate 
diabetes and their major effective compounds 
 
 
Species 
 
Major effective 
compounds 
 
Mechanism 
 
References 
Agaricus 
bisporus 
Dehydrated fruiting body 
extracts, high amount of 
acidic polysaccharide 
Lower blood glucose and 
cholesterol level 
(Fukushima,  
et al., 2001) 
Agrocybe 
cylindracea 
Glucan and heteroglycan Hypoglycemic activity (Wang et al.,  
2002) 
Agaricus 
campestris  
 
Aqueous fruiting body 
extracts 
Anti-hyperglycemic, 
insulin releasing and 
insulin-like activity 
(Gray & 
Flatt, 1998) 
Agaricus 
subrufescens 
 
Beta-glucans and 
oligosaccharides  
 
Anti-hyperglycemic and 
improves pancreatic beta 
cells through inhibition 
of α-glucosidase 
(Liu  et al., 
2008) 
 
Agaricus 
blazei 
Beta-glucans and 
oligosaccharides 
Improved insulin 
resistance 
(Hsu et al.,  
2007) 
Auricularia 
auricula  
Water soluble 
polysaccharide from fruit 
body 
 
Lowering plasma 
glucose, insulin, urinary 
glucose and food intake 
(Yuan et al., 
1998) 
Coprinus 
comatus  
 
Vanadium 
 
Maintains a low level of 
blood glucose and 
improves glucose 
tolerance 
(Han & Liu, 
2009) 
Cordyceps 
sinensis 
 
Polysaccharide CSP-1 CSP-1 may stimulate 
pancreatic release of 
insulin and/or reduce 
insulin metabolism 
(Li  et al., 
2006) 
Ganoderma 
lucidum  
Polysaccharides 
(Ganoderan A and B, 
glucans) 
Strong α-glucosidase 
inhibition and lowered 
the serum glucose levels 
(Zhang & 
Lin, 2004) 
 
Grifola 
frondosa  
Alpha-glucan 
(MT-alpha-glucan) and 
methanol of fruit bodies 
 
Effect on insulin 
receptors (increase 
insulin sensitivity and 
ameliorating insulin 
resistance) and α-
glucosidase inhibitor 
( Matsuura et 
al., 2002; Lo 
et al., 2008) 
Hericium 
erinaceus  
 
Methanol extracts  Hypoglycemic effects 
with lower elevation rate 
of blood glucose level 
(Wang et al., 
2005) 
Inonotus 
obliquus  
 
Dry matter of culture 
broth 
Anti-hyperglycemic 
activity 
(Sun  et al., 
2008) 
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Table 2.2, continued. 
 
Species Major effective compounds Mechanism References 
Lentinus 
edodes 
Exo-polymer Hypoglycemic effect 
with lower blood glucose 
level 
(Yamada  et 
al., 2002) 
Pleurotus 
pulmonaris 
aka 
P. sajur caju 
Aqueous extracts of the 
mushroom 
Reduced the serum 
glucose level in alloxan-
treated diabetic mice and 
increased glucose 
tolerance 
(Li et al., 
2010). 
T. versicolor 
Tremella 
aurantia 
β-glucan–protein 
complex 
glucuronoxylomannan 
exhibited hypoglycemic  
and ameliorated the 
symptoms of diabetes 
(Kiho  et al., 
2000) 
Tremella 
fuciformis  
Exopolysaccharide 
(submerged mycelial 
culture) and 
Glucuronoxylomannan 
(fruit bodies) 
Reduced blood glucose 
levels and improve 
insulin sensitivity 
(Cho  et al., 
2007) 
Wolfiporia 
cocos, 
Laricifomes 
officinalis, 
Fomitopsis 
officinalis 
and  
Laetiporus 
sulphureus 
Dehydrotrametenolic 
acid 
Acts as an insulin 
sensitizer in glucose 
tolerance tests and 
reduces hyperglycemia 
(Sato  et al., 
2002) 
Wolfiporia 
extensa 
(Poria 
cocos) 
Dehydrotumulosic acid, 
dehydrotrametenolic 
acid, pachymic acid 
extracts and triterpenes 
Reduced postprandial 
blood glucose levels and 
enhanced insulin 
sensitivity 
(Sato  et al., 
2002) 
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treatment of DM and its complications, further isolation and research is needed (Perera 
& Li, 2011). Mushroom does not only appear to be effective to control blood glucose, it 
also has a potential in controlling the modification caused by diabetic complications 
because it is capable of producing bioactive metabolites that directly act upon glucose 
metabolism and related biochemical pathways (Silva et al., 2012). As an example, G. 
frondosa, which does not only possess hypoglycemic action in type 2 DM patients but 
also helps in maintaining optimum cardiovascular functions and healthy circulatory 
system (Lindequist et al., 2005; Shavit et al., 2009). Matsuura et al., (2002) reported 
that G. frondosa also contains α-glucosidase inhibitors whereas Xiao et al., (2011) 
reveals that its polysaccharide is a potent anti-diabetic agent with considerably strong 
hypoglycemic activity and high potency of increasing insulin sensitivity. Previous 
clinical research has shown that several triterpenes; ganoderans A, B, C and a ganopoly 
(polysaccharide extract) that are isolated from G. lucidum fruit bodies have been shown 
to have a strong hypoglycemic effect (Lindequist et al., 2005). Meanwhile, the 
development of bioactive compounds isolation from basidiocarps and mycelia of many 
other mushrooms including Agaricus bisporus, Agaricus subrufescens, G. frondosa, P. 
ostreatus, and Cordyceps sinensis as curative drugs for DM and its complications has 
been a great demand (Barra et al., 2012).  
 
2.6.2 Anti-diabetic Research Related to Pleurotus Species 
 Pleurotus species or also known as oyster mushrooms is the third most popular 
cultivated edible mushrooms after Agaricus bisporus and Lentinula edodes (Chang, 
2008) and being an important culinary mushroom all over the world (Abdullah et al., 
2012). According to Guzman (2000), several species of Pleurotus are widely used by 
traditional practitioner for treating approximately 35 diseases. Thus, due to increasing 
market demand, the cultivation of the oyster mushroom has also increased greatly 
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throughout the world in the last few decades (Banik & Nandi, 2004).  
 In addition, Pleurotus species have been discovered to have definite nutritive 
and medicinal values because it contains a number of biologically active compounds, 
dietary fibres, essential amino acid with various therapeutic activities including anti-
diabetic, antioxidant, antimicrobial, antiviral, anti-tumour, anti-inflammation, lower 
blood lipid concentrations, prevent high blood pressure, atherosclerosis, and 
antithrombotic activities (Jayakumar et al., 2006; Chirinang & Intarapichet, 2009; 
Agrawal et al., 2010; Vamanu et al., 2011). It has been reported that, polysaccharides 
from P. tuber-regium and P. abalones showed effective antidiabetic property, 
antioxidant substances and boost immunity (Badole et al., 2006; Huang et al., 2012). 
Moreover, novel antioxidant polysaccharide-peptide complex LB-1b from the 
basidiocarps of P. abalone mushroom exhibited a high antioxidant activity with a 
significant hypoglycemic effect (Li et al., 2012a). Pleurotus ostreatus extract was more 
effective in decreasing the genetic alterations and sperm abnormalities in diabetes 
conditions and could reduce the high blood glucose level in hyperglycemic rats (Ghaly 
et al., 2011). Another important species, the P. eryngii has been tested for insulin 
resistance, anti-hyperglycemic and anti-hyperlipidemic effects in mice. Moreover, 
dietary polysaccharides from this species significantly improved insulin sensitivity 
(Kim et al., 2010). Water-soluble polysaccharides from P. citrinopileatus demonstrated 
enhanced insulin secretion and inhibited the increased of blood glucose level (Hu et al., 
2006b).  
 
2.7 Pleurotus pulmonarius (Fr.) Quél. (Grey Oyster Mushroom) 
 More than 1000 species of Pleurotus have been described throughout the world, 
in more than 25 related and/or confused genera. However, only approximately 50 valid 
species are recognized in Pleurotus. Other popular Pleurotus species are P. ostreatus, P. 
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cornucopiae, P. florida, P. eryngii, P. cystidiosis, P. flabellatus, P. cornucopie and P. 
ostreatoroseus (de Carvalho et al., 2010) that were majorly produced in China (Chang 
& Miles, 2004). 
 Many of the mushroom growers, manufacturers and cultivators often marketed 
P. pulmonarius using the incorrect name P. sajor caju. Some other researchers believed 
that P. pulmonarius is a synonym of the species P. sajor caju. It was also being called 
by several other names such as P. sapidus (Shnyreva et al., 2012). According to index 
of fungorum, P. sajor caju no longer exist. The scientific classification of P. 
pulmonarius is from fungi, basidiomycota, agaricomycotina, agaricomycetes, 
agaricomycetidae, agaricales and pleurotaceae. These species are easily confused due to 
their similar morphology and substrate specificity. However, compare to other 
Pleurotus species, P. pulmonarius has a favourable properties such as tolerant to high 
temperature, fast fruiting and yield efficiencies and also can grown in warmer weather 
(Akinmusire, 2011).  
 Pleurotus pulmonarius is called oyster mushroom because of the shell-like, 
spatulate pileus with eccentric or lateral stipe (Figure 2.1) (Ohga, 2000). Currently, 
Pleurotus pulmonarius a.k.a P. sajor caju is cultivated throughout the world at a rapid 
rate due to high demand as it is popularly consumed (Gregori et al., 2007; Gern et al., 
2008). Moreover, this species can be cultivated within a wide range of temperatures on 
various natural resources and agricultural wastes such as cereal straws, sawdust and 
banana leaves (Poppe, 2004). Nowadays, this species become the major types of non-
agaric mushroom that are cultivated on a large scale (Fu et al., 2006). Previous research, 
Alam et al., (2008) suggested that there are different nutritional values in the different 
part of cultivated mushrooms but according to Icons of Medicinal Fungi from China, 
part with the most medicinal properties of this mushroom is in the basidiocaps which 
are low in calories, carbohydrate, and calcium (Ying et al., 1987; Chang & Miles, 
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2004).  
 Pleurotus pulmonarius and its extracts may have possible medicinal applications 
for a wide range of conditions. Apart from having potential anti-diabetic property, P. 
pulmonarius was able to reduce the total plasma cholesterol and triglyceride level and 
thus reduce the chance of atherosclerosis and other cardiovascular and artery related 
disorders. P. pulmonarius also has hypertensive effects through its active ingredients, 
which affect the renin-angiotensin system. These medicinal properties might be due to 
the presence of some important substance in certain dietary mushrooms (Chang & 
Buswell, 1996).  
 Previously, Kanagasabapathy (2012) has reported that glucan-rich 
polysaccharide of P. pulmonarius can serve as a potential agent for prevention of 
glucose intolerance, insulin resistance and inflammation. In addition, P. pulmonarius 
extract with acarbose produced a greater synergistic anti-hyperglycemic effect than 
either acarbose agent alone (Badole et al., 2008). It also has substances in aqueous 
extract, hot water extracts with antihyperglycemic effect, hypoglycemic activity and 
increasing glucose tolerance (Wang et al., 2011). Discovery of the great potential of P. 
pulmonarius, its usefulness in the prevention of DM. Other than containing low fat, 
high soluble fiber, very little lipid and starch, it also contains a good quality proteins 
and vitamins such as B1, B2 , and C (Kanagasabapathy et al., 2011).  
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Figure 2.1: Basidiocarps of P. pulmonarius 
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3.0 MATERIALS AND METHODS 
3.1 Preparation of P. pulmonarius Fruit Bodies 
 Fruiting bodies of P. pulmonarius used in this experiment were purchased from 
the hypermarket. The sample was washed with distilled water for several times and 
cleaved into small pieces. Fruit bodies were kept in freeze-drying flasks, -20 °C and 
later subjected to freeze-drying. Freeze-dried mushroom was then ground using a dry 
grinder to obtain fine powdered sample. The freeze-dried samples were bottled and kept 
in dry container at room temperature before extraction. 
 
3.2 Preparation of Solvents and Protein Extracts of P. pulmonarius  
 The bioactive compounds present in the mushroom fruit bodies of P. 
pulmonarius were extracted using four different methods. They were polysaccharide 
extraction, methanol extraction, dichloromethane extraction, and crude aqueous 
extraction procedures (Figure 3.1). All the extracts were kept in 4 °C prior to analysis. 
 
3.2.1 Methanol and Dichloromethane Extracts 
 Ground freeze-dried P. pulmonarius powder was weighed and soaked with 
methanol and dichloromethane solvents separately in Schott Duran bottle at a ratio of 
1:10 each. Then each mixture was left on a shaker for 100 rpm overnight at room 
temperature. The mixture was then filtered using a vacuum pump and the filtrate was 
collected. 
 The volume of remaining residue from methanol and dichloromethane extraction 
was measured and repeatedly soaked again with an equal amount of the solvents at a 
ratio of 1:1 separately. The mixture was left on shaker for 100 rpm overnight and 
filtered on the next day. Both filtrates from each extraction were then pooled. Total 
filtrates from each extraction was then subjected to rotary evaporation and the semi- 
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Figure 3.1: Schematic diagram of mushroom extraction procedures, anti-diabetic 
assays, SDS-PAGE, HPLC and MALDI-TOF/TOF MS analysis 
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solid sample was bottled and stored at 4 °C. Yield of extract was determined by 
weighing the semi-solid extract. 
 
3.2.2. Polysaccharide Extracts 
 Ground freeze-dried fruiting bodies of P. pulmonarius (30 g) was weighed and 
soaked in 900 ml of distilled water at 1:30 ratio. The mixture was then homogenized 
using a blender for almost 3 minutes and the homogenate was later boiled for 3 hours. 
Boiled mixture was then left to cool at room temperature and filtered using vacuum 
pump. Filtrate (200 ml) was added to same amount of 75% ethanol (1:1 ratio) and the 
mixture was left at 4 °C overnight. 
 The filtrate-ethanol mixture was centrifuged at 4000 rpm for 15 minutes at 4 °C. 
Supernatant was discarded and the precipitate was then subjected to rotary evaporation 
prior to freeze drying and the dried sample was then bottled and stored at 4 °C. Yield of 
extracts was determined by weighing the dried extract. 
 
3.2.3 Crude Aqueous Extracts  
 Ground freeze-dried P. pulmonarius powder (30 g) was weighed and soaked in 
300 ml distilled water (ratio 1:10). The mixture was then homogenized using a blender 
for almost 3 minutes. The homogenate were separated by filtration using a vacuum 
pump and the filtrate was collected. To obtain a clear supernatant, it was centrifuged at 
5000 rpm for 20 minutes at 4 °C. The pellet formed was discarded while the supernatant 
referred as aqueous extracts was freeze-dried and kept at -20 °C until further analysis. 
 
3.2.4 Preparation of Protein Fraction Using Ammonium Sulphate Precipitation 
One litre of crude aqueous extract obtained above (Section 3. 2. 3) was subjected 
to ammonium sulphate ((NH4)2SO4) precipitation, followed by dialysis and protein 
estimation. The beaker containing supernatant was continuously stirred at 4 °C and 
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covered with parafilm. A sufficient amount of solid ammonium sulphate were 
calculated and weighed to prepare the desired 10 to 100% salt saturation (F10-F100) 
solutions according to the nomogram (Table 3.1). Ammonium sulfate salt was added 
slowly and constantly stirring. Salt was allowed to dissolve completely before addition 
of the remaining salt. Once all have been added, the mixture was left to sit for 45 
minutes on an ice bath with continuous stirring.  
Then the mixture was centrifuged at 10 000 rpm for 30 minutes (4 °C) to 
separate the precipitated protein from the solution. Precipitated protein was recovered 
by re-suspending it gently in 1 ml of distilled water by a quick vortex and transferred to 
a clean tube and kept at 4 °C, prior to dialysis. Supernatant will be subjected to further 
gradual addition of ammonium sulphate to pellet out proteins with various 
hydrophobicity. 
 The protein suspension was transferred to visking dialysis tubing, Snake SkinTM 
Pleated Dialysis Tubing, 3 500 molecular weight cut-off (MWCO). The required length 
of tubing was pulled out from the stick and cut to the appropriate size. The amount of 
tubing required was calculated by assuming ~3.5 ml sample per cm of dry tubing. The 
open ends of the tubing were briefly dipped for 5 seconds in distilled water. 
 A knot was tied and tightly pulled at one of the open end. Precipitated protein 
fraction was added through the other open end of the tubing, which was then securely 
tied as well. The dialysis tubing containing protein samples was immersed in distilled 
water at 4 °C with continuous stirring for 48 hours with four times water change. The 
dialysate was then freeze-dried and stored at -20 °C and referred as (NH4)2SO4 protein 
fractions. 
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Table 3.1: Nomogram for determination of ammonium sulphate (NH4)2SO4 amount 
needed for each percentage (%) of saturation. 
 
  
  10 20 30 40 50 60 70 80 90 100 
Original 
Saturation 
 Quantity (gram) of ammonium sulphate (NH4)2SO4 must be 
added to 1 liter of distilled water 
0 56 114 176 243 313 390 472 561 662 767 
10  57 118 183 251 326 406 494 592 694 
20   59 123 189 262 340 424 520 619 
30    62 127 198 273 356 449 546 
40     63 132 205 285 375 469 
50      66 137 214 302 392 
60       69 143 227 314 
70        72 153 237 
80         77 157 
90          79 
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3.2.5 Measurement of Total Protein in P. pulmonarius Crude Aqueous Extracts 
and Protein Fractions 
 Following semi-purification by (NH4)2SO4 precipitation and dialysis process, 
protein fractions F10-F100 were subjected to protein estimation using Pierce BCA 
Protein Assay Kit according to the protocols recommended by the manufacturer. 
Bicinchoninic acid (BCA) is a calometric procedure for quantification of protein. The 
BCA assay measures the formation of Cu+ from Cu2+ by the Biurett complex in alkaline 
solutions of protein using bicinchonic acid (BCA). 
 A volume of 25 µl of each standard or unknown sample replicate were pipetted 
into a microplate well (working range 20-2000 µg/ml). A range of bovine serum 
albumin (BSA) concentrations (0-2 mg/mL) was used to construct a standard curve. 
Preparation of standard Diluted Albumin (BSA) Standards can be referred to Appendix 
1.1(a). 
 Working reagent (200 ml) was added to each well of 96 wells microplate and 
mixed thoroughly on a plate shaker for 30 seconds (Appendix 1.1(b)). The plate was 
covered and the solution was incubated at 37 °C for 30 minutes. The absorbance was 
measured at 562 nm on a Tecan Sunrise ELISA Reader. All protein determinations were 
completed in triplicate. Pierce BCA Protein Assay Kit instructions from product’s 
manufacturer can be referred in Appendix 1.1 (c). 
 
3.3 Preparation of Extracts Stock Concentration 
 For crude aqueous solution preparation, 10 mg of freeze dried sample were 
weighed and dissolved in 10 ml of distilled water in order to prepare 10 mg/ml stock 
solutions. For polysaccharide, methanol and dichloromethane dried extracts, yield 
obtained was weighed and dissolved in distilled water in order to prepare 5 mg/ml of 
stock solutions prior use. All the solutions were mixed well by using a vortex mixer. 
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The solutions were then kept at -20 oC for further use. To obtain the desired 
concentration for each assay, the sample stock solutions were subjected to serial dilution 
using appropriate amount of distilled water. 
 
3.4 In vitro Screening of P. pulmonarius Extracts for Anti-diabetic Enzyme 
Inhibitory Activities 
 Two anti-diabetic inhibition assays were used in this experiment; S. cerevisea α-
glucosidase inhibitory assay and porcine pancreatic α-amylase inhibitory assay.  
 
3.4.1 In vitro Screening of S. cerevisiae Alpha Glucosidase Inhibitory Activity 
Assay 
 The determination of α-glucosidase inhibitory activity was performed by the 
spectrophotometric method according to Apostolidis et al., (2006) and Kim et al., 
(2004) with modification. This assay was carried out in the dark due to p-nitrophenyl-α-
D-glucopyranoside used is light sensitive. Alpha glucosidase enzyme from S. cerevisiae 
(Type 1) (Sigma Aldrich Co) was chosen in this anti-diabetic inhibitory assay. 
 Sample from stock solution for each solvent extraction and protein fraction with 
different concentration were prepared and labelled. For crude aqueous, methanol, 
dichloromethane and polysaccharide extracts, 25 mg/ml concentration were prepared 
while 25 µg/ml protein concentration for F10-100 protein fractions. 
 For α-glucosidase inhibitory assay, a volume of 250 µl of each sample solution 
(all crude extracts and protein fractions with varying concentrations prepared) and 250 
µl of 1.0 M potassium phosphate buffer at pH 6.9 (Appendix 1.2.1(a)) containing α-
glucosidase solutions (0.1 U/ml) (Appendix 1.2.1(d)) were premixed in a test tubes. All 
extracts were carried out in three replications.  
 For control, 250 µl of distilled water was added to replace the amount of sample 
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used and contained only distilled water, enzyme and substrate. Furthermore for positive 
controls, voglibose was used. Preparation of voglibose was described in Appendix 
1.2.1(e). 
 The mixtures were then pre-incubated at 37 °C for 2 minutes. After the pre-
incubation, 250 µl of p-nitrophenyl-α-D-glucopyranoside in phosphate buffer 
(Appendix 1.2.1(b)) was added to the mixtures as a substrate at 5 seconds intervals to 
start the reaction. The reaction mixture was further incubated for another 30 minutes at 
37 °C. The catalytic reaction was terminated by addition 2 ml of 0.1 M sodium 
carbonate (Na2CO3) solution to each sample (Appendix 1.2.1(c)).  
 Alpha glucosidase inhibitory activity was determined by measuring the release 
of p-nitrophenol from p-nitrophenyl- α -D-glucopyranoside at 405 nm by using a 
Shimadzu UV Mini 1240 spectrophotometer. The α-glucosidase inhibitory activity 
under experimental condition was expressed as percentage of inhibition and was 
calculated by following formula: 
 
Percentage of Inhibition = [(A405Control −  A405Extract)]  ×  100A405Control  
 
Where, A405Extract = OD 405 value with sample extracts, of p-nitrophenyl- α-D-  
  glucopyranoside and α-glucosidase A405Control = OD 405 value with p-nitrophenyl-α-D-glucopyranoside and α- 
  glucosidase  
 
 Distilled water was served as a blank for correcting the background absorbance. 
The activity in controls (with an enzyme but without inhibitor) was considered to be 
100% activity. The percentage of α-glucosidase inhibition was plotted against different 
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sample extracts to identify active samples for further study. 
 
3.4.2 In vitro Screening of Porcine Pancreatic Alpha Amylase Inhibitory Activity 
Assay 
 The α-amylase inhibition assay was adapted from Apostolidis et al., 2007 with 
some modifications. Porcine pancreatic α-amylase was purchased from Sigma Chemical 
Co. According to the manufacturer product description, one unit of amylase enzyme 
will liberate 1.0 mg of maltose from starch per minute at pH 7.0 at 20 °C. 
 Sample from stock solution of solvent extracts and protein fractions at different 
concentrations were prepared and labelled. For crude aqueous, methanol, 
dichloromethane and polysaccharide extracts, 25 mg/ml concentration were prepared 
while 25 µg/ml protein concentration for F10-100 protein fractions. 
 Sample extracts and protein fractions (1 ml) were pre-mixed in 1 ml of 0.02 M 
sodium phosphate buffer pH 6.9 (Appendix 1.2.2(a)) with 0.006 M sodium chloride 
containing 0.5 mg/ml α-amylase (Appendix 1.2.2(d)). The mixture solution was pre-
incubated in a water bath at 37 °C for 5 minutes. For control, 1 ml of distilled water was 
added to replace the amount of sample used and contained only distilled water, enzyme 
and substrate. Furthermore for positive control, acarbose was used (Appendix 1.2.2(e)).  
 After pre-incubation, 1 ml of a starch solution (substrate) in 0.02 M sodium 
phosphate buffer, pH 6.9 with 0.06 M sodium chloride (Appendix 1.2.2(b)) was added 
to each tube at predetermined time intervals. The reaction mixtures were then incubated 
again at 37 °C for 10 minutes. The reaction was stopped by directly transferring the 
reaction mixture to a boiling water bath (100 °C) and 2 ml of dinitrosalicyclic acid 
(DNS) colour reagent was quickly added while boiling (Appendix 1.2.2(c)). The test 
tubes were incubated in boiling water bath for 15 minutes.  
 The reaction mixture was cooled to room temperature before being diluted with 
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the addition 5 ml of distilled water. This reaction (corresponding to a colour change 
from orang-yellow to red) is detectable at 540 nm using Shimadzu UV Mini 1240 
spectrophotometer. Experiments were performed in three replicates for each sample. 
The α-amylase inhibitory activity under experimental condition was expressed as 
percentage of inhibition and was calculated by following formula: 
 
Percentage of Inhibition = [(A540Control −  A540Extract)]  ×  100A540Control  
Where, A540Extract = OD 540 value with sample extracts, starch and α-amylase enzyme A540Control = OD 405 value with starch and α-amylase 
 
 Distilled water was served as a blank for correcting the background absorbance. 
The activity in control (with an α-amylase enzyme but without inhibitor) was 
considered to be 100% activity. The percentage of α-amylase inhibition was plotted 
against different sample extracts to identify active samples for further study. 
 
3.5 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Analysis to Profile Proteins in Protein Fractions 
 Molecular weight pattern for each protein was profiled through sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) that was performed based on 
the continuous buffering system by using method from Laemmli (1970), with some 
modifications.  
 Active protein fractions that showed the highest inhibition for the in vitro 
screening assays were subjected to SDS-PAGE analysis. For α-glucosidase assay, F30 
protein fraction was selected while for α-amylase assay, F100 protein fraction was 
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selected. SDS-PAGE was used in this experiment to observe the protein profile of each 
fraction. Preparation of stock solutions for glycine SDS-PAGE system was attached as 
Appendix 1.3. 
 
3.5.1 Preparation of Separating and Stacking Gels 
 The protein fraction with highest enzyme inhibitory activity was loaded on to 
16% separating gel SDS-PAGE with 4% stacking gel in vertical gel electrophoresis 
system. The 2 sets of vertical slab gel units were rinsed with distilled water and 
assembled vertically. Spacer strips with the thickness of 0.75 mm spacer strips were 
placed at both edges of the plates. The solutions of 16% separating gels (Appendix 
1.4.1) were mixed well and poured into each sandwich using a pipette. TEMED and 
10% APS were freshly added to the mixture prior to pouring into gel-casting apparatus.  
 Then each poured gel was overlaid with distilled water. The separating gel was 
allowed to polymerize at room temperature for a minimum of 1 hour. Before pouring 
the stacking gel, the overlaid distilled water was removed by slanting the gel assembly. 
The gel surface was rinsed with 1 or 2 ml of stacking gel solution, which was then 
removed. 
 The stacking gel solution (Appendix 1.4.2) was poured onto the separating gel 
and a comb was then inserted. It is important to avoid trapping any bubbles below the 
teeth of the combs to ensure a successful protein transfer. The gel was left at room 
temperature for at least 2 hours to polymerize. The polymerized gel with the comb in 
place can be stored overnight in 4 °C refrigerator.  
 In this experiment, a molecular weight markers (Pre-stained Protein Marker, 
Broad Range 6-175 kDa) protein ladder was used to ensure the correct molecular weight 
of desired band was observed. The pre-stained protein marker stock solution was shook 
to mix the solution and stored as aliquot in eppendorf tubes to reduce contamination and 
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later kept in -20 °C freezer. Prior to use the marker was heated to 95 °C to 100 °C for 3-
5 minutes. A quick microcentrifuge spin was applied before loading it into a gel. 
 
3.5.2 Gel Electrophoresis Running Procedure  
 Samples with determined concentration and sample buffer were mixed at 1:3 
ratios for SDS-PAGE and then boiled for 5 minutes. For the screening purposes 12 µl of 
each selected protein fraction (F10-F100) was used. The casted sandwiches were placed 
in the dual tank. The tank buffer was filled into dual vertical mini-gel unit tank. The 
combs were slowly removed from the gels and overfilled with tank buffer.  
 Appropriate volume of samples from selected protein fractions and molecular 
weight markers (pre-stained protein marker, broad range (6-175 kDa) for 16% gel thick 
was filled into the wells. The wells without sample or standard solution were loaded 
with sample buffer. Electrophoresis was performed using Bio-Rad Power Pac 300 at 
constant voltage of 60 V for the first 15 minutes followed by gradual increased to 80-
100 V, to avoid excess heat generated. When the blue dye front reached approximately 
1 cm from the bottom of the gel, the power supply was turned off and power cable was 
disconnected. The gels were then stained with Coomassie Brilliant Blue. The gels were 
be treated immediately to prevent band diffusion and the image was then captured. 
 
3.5.3. Comassie Brilliant Blue Staining Protocols 
 To visualize the protein bands, the 16% acrylamide gel was stained with 
Coomassie Brilliant Blue R-250. The stacking gel was removed and discarded from the 
SDS-PAGE gel. The remaining gel was placed in a transparent container that contained 
staining solution (Appendix 1.5(a)). Sufficient volume of staining solution was added 
until the gel freely floated. It was shook slowly for 30 minutes on an orbital shaker. To 
accelerate staining, the staining solution was heated at 45 °C prior to use.  
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 The staining solution was then replaced with de-staining solution (Appendix 
1.5(b)). Addition of Kimwipe tissue was added to the corner of the tray will help 
remove Coomassie blue from the gel without much changing of the de-staining 
solution. The de-staining solution was frequently replaced until suitable gel background 
was achieved and gave a good protein band resolution. For better results, gel with de-
staining solution was left overnight with gentle shaking on an orbital shaker. De-
staining process was stopped by washing the gel several times with distilled water. 
 
3.6 Purification of Selected Active Protein Fractions by Reversed-Phase High 
Performance Liquid Chromatography (RP-HPLC) Analysis 
 After gel image for protein fraction screening was obtained, there were two 
active protein fractions which showed high percentage of preliminary inhibition assays 
for α-glucosidase inhibitory activity (F30 protein fraction) and α-amylase inhibitory 
assays (F100 protein fraction). Both fractions showed a different range of observed 
bands and protein molecular weight thus either one is responsible to treat diabetes 
mellitus. The protein fraction that has show active inhibition activity was further 
purified by reversed-phase high performance liquid chromatography (RP-HPLC).  
 Two different columns were used in this experiment; analytical column for 
protein profile analysis (Table 3.2) and a semi-preparative column for protein collection 
(Table 3.3). Analytical column was used for a protein profile analysis and to optimize 
solvent system; 1 mg/ml of protein fractions concentration was used by using a 20 µl 
loop while for collection purpose protein fractions 2 mg/ml was used using a 
preparative column with 200 µl loop. The freeze-dried samples were diluted with 
distilled water and transferred to 1.5 ml eppendorf tubes and then centrifuged at 4000 
rpm for 3 minutes to precipitate any particulate matter and to get clear solution. The 
samples were stored at 4 °C until analysis. 
 43 
 Chromatographic optimization of a separation was accomplished using RP-
HPLC Shimadzu Model (RP-HPLC) from Japan. An analytical column, which is 
Waters Atlantis Column (4.6 mm x 250 mm x 5 µm particle size) and a preparative 
column, Chromolith SemiPrep RP-18 endcapped 100-10 mm for a protein sample 
collection were used. The mobile phase consisted of two solvent systems that includes 
pump A; (0.1% trifluoroacetic acid (TFA) in water (v/v)) and pump B; (100% 
acetonitrile) in a gradient mode (Appendix 1.6). System used to purify was elution 
buffer 0% to 95% acetonitrile for 40 minutes with the flow rate 1.0 mg/ml. 
 All solvents were filtered by cellulose membrane filter paper 0.45 µm and nylon 
membrane filter with Bunchi Filtration system under vacuum, to avoid of air bubbles 
and contamination by any small particles. Prior to the injection to HPLC system, all the 
protein samples after preparation was filtered through the filter disc (13 mm nylon, 0.45 
um) with syringe filter to avoid blockage of the HPLC column. The syringe filter was 
rinsed with 2-3 ml aliquots of the methanol (Appendix 1.6(c)) between each use. 
 Baseline was established prior to the injection of sample. Eluent, which is 100% 
acetonitrile (Appendix 1.6(a)) and 0.1% TFA (Appendix 1.6(b)), was prepared and run 
for few minutes to ensure that the baseline is stable. [Note:  reversed-phase column 
should be flush or “conditioned” for first time use, after long terms storage or when 
changing buffer for a system]. 
 An aliquot of the F30-F100 selected protein fractions extract was analysed by a 
Waters HPLC system with UV-VIS detection (220 and 254 nm) using a Water Atlantis 
Column. A volume of protein sample, which is 20 µl with 1 mg/ml concentration, was 
injected each time into the column with a 20 µl injection loop used, at a flow rate 1 
ml/min. Each of the protein samples for both assays was injected 3 times into the 
column and the corresponding chromatograms were obtained. From these 
chromatograms, the retention times and the areas under the peaks of the protein samples 
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were noted. 
 Peaks detected for particular protein fractions were identified by comparing the 
samples retention time with the baseline at 220 nm and 254 nm. Based on analytical 
chromatographic separation, preparative chromatographic separation was carried out for 
a sample collection. For peak collection, 200 µl of the sample solution with 2 mg/ml 
concentration was injected each time into the column with a 200 µl injection loop. The 
eluted peaks were collected for further used in re-evaluation of the sample for both 
assays. 
 Based on UV detection, several peaks were collected manually. All individual 
HPLC peaks were collected, labelled and kept in 4 °C. Acetonitrile was totally removed 
under a stream of nitrogen gas and the residue (water solution) was freeze-dried. 
Method development for HPLC can be referred at Appendix 1.7. 
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Table 3.2: Analytical reversed-phase HPLC parameters for profiling  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3: Semi-preparative reversed-phase HPLC parameters collection of samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Parameter Condition 
Column Waters Atlantis Column  
(4.6 mm x 250 mm x 5 µm),  
RP-HPLC 
Mobile phase Acetonitrile: 0.1% TFA with distilled water  
(Binary gradient)  
Injection volume  20  µl  
Flow rate 1.0 ml/min 
Sample 
Concentration 
1 mg/ml 
Elution System 0% to 95% acetonitrile for 40 minutes  
Detector Signal 
(PDA) 
220 nm  
Parameter Condition 
Column Chromolith SemiPrep RP-18 endcapped  
100-10 mm, RP-HPLC 
Mobile phase Acetonitrile: 0.1% TFA with distilled water  
Injection volume  200 µl 
Flow rate 3.9 ml/min 
Sample 
Concentration 
2 mg/ml 
Elution System 0% to 95% acetonitrile for 40 minutes  
Detector Signal 
(PDA) 
220 nm  
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3.7 Anti-Diabetic Enzyme Inhibitory Assays of RP-HPLC Purified Protein 
 Following fractionation by RP-HPLC, all peaks obtained from the 
chromatogram were re-evaluated again by α-glucosidase and α-amylase assays. For α-
glucosidase inhibitory assay, the protein concentration use (F30 protein fraction) was 
2.5 µg/ml which was 10 fold diluted from the previous assay (section 3.4.1). Similarly, 
6.25 µg/ml protein (F100 protein fraction) was used for α-amylase assay which was 
four fold diluted compound to the previous assay 3.4.2. The experiments for anti-
diabetic assays were carried out as described in Section 3.4. 
 
3.8 SDS-PAGE Analysis of Active RP-HPLC Separated Protein Fractions 
 In this experiment, SDS-PAGE analysis was used to characterize the degree of 
purity and also the preparation for in-gel digestion prior to Matrix Assisted Laser 
Desorption/Ionization-Time of Flight/Time of Flight Mass Spectrometry (MALDI-
TOF/TOF MS) analysis. From the re-evaluation of anti-diabetic assays (Section 3.4), 
the selected HPLC purified protein that showed the highest activity for each assays were 
subjected to SDS-PAGE analysis.  
 In the case of in-gel digestion for MALDI-TOF/TOF MS analysis, 1µg/µl of 
purified protein fraction was used. All the procedures and reagents preparation for SDS-
PAGE was the same as previous, Section 3.5 and stained with Coomassie Brilliant Blue 
stain (Section 3.5.3). Coomassie staining is easier and more rapid thus Coomassie   
Brilliant Blue staining was first used to stain the gel. However no band was observed. 
Thus, the silver staining method, which is more sensitive was used to detect smaller 
amount of protein. Prior to MALDI-TOF/TOF MS analysis, a compatible silver staining 
was used to avoid permanent binding of the protein to the gel. 
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3.8.1 Silver Staining Protocol for Coomassie-stained 16% polyacrylamide gel (MS 
Compatible) 
 Mass spectrometry compatible silver staining method used was conducted 
according to Shevchenko et al., (1996) with modifications. 
 
3.8.1.1 Protocol of Silver Staining for Coomassie-Stained Protein from SDS-PAGE 
Analysis 
 The Coomassie-stained gel was de-stained as described in Section 3.5.3 
overnight and then rinsed with distilled water. The gel was then soaked in a fixing 
solution (Appendix 1.8(a)) for 30 minutes to overnight with gentle shaking on an orbital 
shaker. 
 Subsequently, it was incubated in the sensitizing solution (Appendix 1.8(b)) for 
another 30 minutes. The gel was then washed three times for 5 minutes each with 
distilled water. The gel was then stained in the silver stain solution (Appendix 1.8(c)) 
for 20 minutes. Prior to developing step, the gel was washed again with distilled water 
for a few seconds and the water was poured off.  
 Then small volumes (3-5 ml) of developing solution (Appendix 1.8(d)) was 
added, swirled briefly, and then discarded. Development took 4-5 minutes or until the 
protein bands were nicely resolved. The gel was rinsed quickly with distilled water and 
gels development was blocked by placing it in a stop solution (Appendix 1.8(e)) for 10 
minutes. The gels were replaced and stored in distilled water for further use. 
 
3.8.1.2 Preparation of Silver-Stained Protein SDS-PAGE for MALDI-TOF/TOF 
MS Analysis 
 De-stained gel with a clear protein band from MS compatible silver staining was 
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observed and image was captured. The gel was transferred to a clean culture dish and 
unnecessary parts (top, bottom, MW marker lanes) was cut away with a sterile scalpel 
and blade, leaving only the lanes with proteins of interest. All protein bands were 
excised as precise as possible. Any diffused stained edge to the band was removed.  
 All excess stain was removed otherwise residual stain may interfere with data 
acquisition. Each gel slice was placed into a plain 1.5 ml eppendorf tube. Fresh scalpel 
was used to cut up each slice and the same scalpel used to transfer the cut up slices to 
the labelled tube. The gel slice was washed with distilled water at least 2 times for 10 
minutes with occasional vortex mixing. Wash solution was discarded. Small plastic 
pipette tips were used (10 µl -100 µl) to remove the solution. Work was quickly as 
possible because the gel becomes stickier as it dries out. 
 
3.9 Protein Identification by MALDI-TOF/TOF Mass Spectrometry Analysis 
 
 Two digestion protocols were applied for the MALDI-TOF/TOF MS analysis; 
the in-solution and in-gel digestion. The in-solution digestion involved the protein 
samples which were collected from HPLC protein fractions and could directly be 
characterized by MS meanwhile for in-gel digestion, it was necessary to efficiently 
recover the proteins from the SDS-PAGE gel. In this experiment, both protocols of 
MALDI-TOF/TOF MS were used and compared. 
 
3.9.1 In-Solution Digestion Protocol of MALDI-TOF/TOF Mass Spectrometry for 
Protein 
 MALDI-TOF/TOF MS analysis was performed at the Proteomic Facilities in 
Medical Biotechnology Laboratory, Faculty of Medicine, University of Malaya. 
Procedure used in this experiment was modified from Pierce In-solution Tryptic 
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Digestion Kit.  
 Following re-evaluation bioassay of several HPLC fractions, the peak that 
showed the highest inhibition of α-glucosidase inhibitory assay was furthered to 
MALDI-TOF/TOF MS analysis. This is for identification of the purified proteins and 
measuring the mass more accurately. Protein samples were prepared as previously 
described in Section 3.2.4.2. 
 The in-solution MALDI-TOF/TOF MS analysis worked well with protein 
concentrations in the range 0.1-1.0 mg/ml (Appendix 1.9(e)). The protocol of in-
solution tryptic digestion was divided to three steps; reduction and alkylation, followed 
by digestion and extraction. 
 
A. REDUCTION & ALKYLATION: 
 Fifteen µl of 50 mM ammonium bicarbonate (digestion buffer) was prepared 
(Appendix 1.9(a)) and 1.5 µl of 100 mM DTT (reducing buffer) (Appendix 1.9(b)) were 
added to a clean 500 µl microcentrifuge tube. Ten-μl protein sample containing 10 μg of 
protein was added to the tube and the final volume adjusted to 27 µl with ddH2O. The 
sample was incubated at 95°C for 5 minutes. The sample was then left to cool at room 
temperature. Alkylation buffer (100 mM iodoacetamide) (Appendix 1.9(c)) was freshly 
prepared and 3 µl of the buffer was added to the tube. The mixture was then incubated 
in the dark at room temperature for 20 minutes. 
 
B. DIGESTION: 
 Stock solution, 0.1 µg/µl of trypsin (Appendix 1.9(d)) was prepared separately. 
Trypsin (2 µl) was added to the reaction tube and incubated at 37 °C for overnight. The 
mixture was then vortexed briefly and spun down at 1000 rpm for 1 minute. 
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C. EXTRACTION: 
 The mixture was shaken with 50 µl of 50% acetonitrile for 15 minutes. All 
liquid was transferred to fresh tubes. The mixture was then mixed with another 50 µl of 
100% acetonitrile for 15 minutes. The liquid then transferred to the previous tube. The 
digested sample was then completely dried by using vacuum at low speed usually for 2 
hours. Unused sample may be frozen at -20 °C in case further analysis is required. The 
samples were furthered to ziptip desalting and spotting.  
 
3.9.1.1 Zip tip protocol (desalting and spotting) 
a. Material and Preparation of solutions 
• Material: C18 ZipTip. Preparation of solutions:  
I. Wetting solution   = 100% acetonitrile  
II. Sample preparation  = 0.1% Formic acid 
III. Equilibrium solution  = 0.1% Formic acid 
IV. Washing solution   = 0.1% TFA 
V. Elution solution   = 0.1% TFA in 50% acetonitrile  
Matrix solutions:  
VI. Buffer A: 2% Acetonitrile; 0.1% TFA; 98% MiliQ water 
VII. Buffer B: 98% Acetonitrile; 0.1% TFA; 2% MiliQ water 
VIII. 10 mg of α-Cyano-4-hydroxycinnamic acid (CHCA) dissolved in (0.4 ml 
buffer A and 0.6 ml buffer B mixture) 
b. Desalting sample protocol: 
Protein samples were reconstituted in 10 µl of 0.1% TFA. Elution buffer (1.5 µl) was 
added into a new tube. 
Pre-wetting:  10 µl of 100% acetonitrile was aspirated and dispensed for three cycles 
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Equilibrate:  To equilibrate tips, 10 µl of 0.1% Formic acid was aspirated and   
  dispensed for five cycles 
Binding:  10 µl of protein samples was passed through the zip-tips repeatedly by 
  pipetting in and out for 10 cycles without completely dry 
Washing:  10 µl of 0.1% TFA was aspirated and dispensed for five cycles 
Elution: 1.5 µl of elution buffer was aspirated and dispensed for three cycles 
Then, the sample was fully dispensed in the sample solution. 
Note: The zip-tip resin should not be completely dry (except for final elution step) after 
aspiration of solution to avoid resin damage and alteration of binding capacity. 
c. Spotting sample: 
 Matrix solution (1.5 µl) was added to 1.5 µl elution buffer (with sample). The 
mixture was mixed well and 3 µl of each sample was spotted on MALDI plate twice. 
Samples were allowed to completely dry before the analysis.  
 The peptides resulted from the in-gel or in-solution solution digestion were 
anaylzed by MALDI-TOF/TOF spectra to obtain the peptides’ masses. The results were 
matched with the translated open frames in database of the National Centre for 
Biotechnology Information (NCBI) and Masscot, Swissprot database. 
 
3.9.2 In-Gel Digestion Protocol for MALDI-TOF/TOF MS Analysis of an SDS-
PAGE Gel Separated, Silver-Stained Protein 
 MALDI-TOF/TOF MS analysis for In-gel digestion was sent to Genome 
Research Centre, The University of Hong Kong (HKU). ABSciex MALDI 4800 
TOF/TOF Analyser was used and the scanning range for general protein identification 
was 900-4000 m/z, reflector mode, then the five most abundant peptides (precursors) 
that are not on exclusion list was selected for further fragmentation (MALDI-TOF/TOF) 
analysis to generate the full scan mass spectrum. Trypsin enzyme was used to digest 
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proteins. Overall schematic diagram for In-gel digestion protocol was simplified in 
Figure 3.2 while sample preparation for zip-tip desalting and detail procedure were 
attached in Appendix 1.10.  
MASCOT (ver. 2.1) & NCBI search analysis settings were as follows: 
Fixed modification: carbamidomethyl (C);  
Variable modification: oxidation (M); 
MSMS Fragment tolerance: 0.2 Da;  
Precursor tolerance: 75 ppm; 
Peptide charge: +1; Monoisotopic 
 
3.10 Statistical Analysis 
 All assays were performed in triplicates and the values were averaged. Each data 
expressed represent the mean ± standard deviation (SD) and was analyzed by using the 
Microsoft Excel 2011. Data significance was performed by one-way analysis of 
variance (ANOVA) by Minitab Release 14 Statistical Software program version 
(14.12.0). Differences of 95% (p<0.05) were considered statistically significant. 
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Figure 3.2: Overall schematic for in-gel digestion protocol done by Genome Research 
Centre, The University of Hong Kong (HKU) 
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4.0 RESULTS 
4.1 Yield of P. pulmonarius Extractable Solutes Using Different Extraction 
Solvents 
 Ground freeze-dried P. pulmonarius basidiocarps were used in this study for the 
preparation of extracts. Freeze drying technique applied to the extract was found to 
remove 83.65% water from the basidiocarps. Powdered samples were soaked in water, 
methanol and dichloromethane to yield aqueous extracts (AE), methanol extracts (ME) 
and dichloromethane extracts (DCME), respectively. Polysaccharide extract (PE) was 
obtained by ethanol precipitation of hot water extract.  
 Yield of extractable solutes using different solvents is shown in Table 4.1. The 
results indicated that highest percentage yield was AE (18.34 %) followed by ME (1%) 
and DCME (0.525%). PE showed the lowest percentage yield of only 0.27%. 
 
4.2 Quantitation of Protein by Pierce BCA Protein Assay Kit 
 Quantitation of total proteins was done in triplicates and the average mean of 
protein concentration was recorded. Protein content was estimated and calculated by 
referring to BSA Standard Curve of Albumin Standard (BSA). Table 4.2 shows the 
protein contents from aqueous extract and protein fractions that were derived from 
ammonium sulphate precipitation. 
 Total protein content (Table 4.2) showed that AE contained the highest amount 
of protein content (3000 µg/ml). Among the protein fractions derived from ammonium 
sulphate precipitation technique, F90 salt saturation solution showed the highest protein 
content of 1820 µg/ml. This is followed by protein fraction with salt saturation F70, F50 
and F60 with 1450, 1550 and 1000 µg/ml protein content, respectively. 
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Table 4.1: Percentage yield of P. pulmonarius extractable solutes using various 
solvents 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
Table 4.2: Protein contentof aqueous extract and protein fractions of P. pulmonarius 
basidiocarps obtained following ammonium sulphate precipitation 
 
 
 
 
 
 
 
 
  
  
Procedure of Extraction Percentage Yield (g/100g dry 
weight) 
Aqueous extracts (AE) 18.34  
Polysaccharide extracts (PE) 0.27  
Methanol extracts (ME) 1.0 
Dichloromethane extracts (DCME) 0.525  
Protein fractions and aqueous 
extracts of P. pulmonarius 
basidiocarps 
Protein concentration (µg/ml) 
F10 60 
F20 90 
F30 190 
F40 450 
F50 1550 
F60 1000 
F70 1450 
F80 790 
F90 1820 
F100 330 
Aqueous extract (AE) 3000 
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4.3 In vitro Screening of Solvents Extracts and Protein Fractions from P. 
pulmonarius for Anti-Diabetic Enzymes Inhibitory Assays 
 Crude extracts (AE, ME, DCME and PE) as well as the ammonium precipitated 
protein fractions (F10-F100) were assayed for the inhibition of α-glucosidase and α-
amylase enzymes. For both anti-diabetic assays, the protein fractions were diluted to 25 
µg/ml protein content and 25 mg/ml for solvents and crude AE. 
 
4.3.1 In vitro Screening for S. cerevisiae Alpha Glucosidase Inhibitory Activity 
Assay 
 Crude extracts (AE, ME, DCME and PE) and protein fractions (F10-F100) were 
tested for α-glucosidase inhibitory activity. The activity was expressed as percentage of 
inhibition (%) shown in Figure 4.1. DCME extract showed the strongest inhibition 
effect of α-glucosidase activity (91.13%) at 25 mg/ml concentration. This is followed by 
sample from PE and AE with 85.82% and 73.50% inhibition respectively. ME showed 
the lowest inhibitory activity against α-glucosidase activity with only 2.61% inhibition. 
The activity was expressed as percentage of inhibition (%) shown in Figure 4.1. 
 Inhibition of α-glucosidase activity by F10-F100 is shown in Figure 4.2. Among 
all the fractions, at 25 µg/ml protein content, F30 protein fraction strongly suppressed 
the activity of α-glucosidase enzyme (24.18%), followed by F60, F80 and F90 fractions 
with 19.57%, 16.94% and 15.82% inhibition respectively. There was no inhibitory 
activity observed for F20 and F100 protein fractions. Majority of the protein samples 
(F30-F90) appeared to be better inhibitors of α-glucosidase enzymes than a known 
inhibitor for α-glucosidase, voglibose. Based on the result, F30 protein fraction was 
selected for further chemical analysis. 
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Figure 4.1: Percentage inhibition of α-glucosidase enzyme activity by crude aqueous, 
polysaccharide, methanol and dichloromethane extracts at 25 mg/ml. (AE= aqueous 
extract, PE= polysaccharide extract, ME= methanol extract, DCME= dicholoromethane 
extract) 
Values were expressed as mean ± SEM of three replicate determinations. Mean values 
with different lower case letters (a-d) indicate significant difference at p < 0.05. 
*Voglibose was used as negative control with the concentration at 25 µg/ml. 
 
Figure 4.2: Percentage inhibition of α-glucosidase enzyme activity by ammonium 
percipitated protein fractions (F10-F100) at 25 µg/ml 
 
Values were expressed as mean ± SEM of three replicate determinations. Mean values 
with different lower case letters (a-e) indicate significant difference at p < 0.05. 
*Voglibose was used as negative control with the concentration at 25 µg/ml. 
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4.3.2 In vitro Screening for Porcine Pancreatic Alpha Amylase Inhibitory 
Activity Assay 
 Crude extracts (AE, ME, DCME and PE) and protein fractions (F10-F100 
protein fraction) both from P. pulmonarius basidiocarps were tested for α-amylase 
inhibitory activity.  
 At 25 mg/ml concentration, AE extracts showed a significant inhibitory action 
against α-amylase activity with 87.74%. This was followed by samples from PE and 
ME with 48.10% and 42.73% inhibition respectively. DCME yielded the lowest 
inhibition activity with only 29.82% activity. The activity was expressed as percentage 
of inhibition (%) (Figure 4.3).  
 Inhibition of α-amylase activity by F10-100 from P. pulmonarius basidiocarps 
was shown in Figure 4.4. Among all the protein fractions at 25 µg/ml, F100 protein 
fraction showed the highest inhibition activity of α-amylase which was 41.80% 
followed by F70 and F90 with 30.98% and 28.99% inhibition, respectively. The 
inhibitory effect of the F70, F90 and F100 appeared to be better inhibitors than a known 
inhibitor for α-glucosidase, acarbose. Among all the crude and protein extracts screened 
for the α-amylase inhibitory assay, F100 protein fraction that showed the best inhibitory 
activity was selected for further chemical analysis. 
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Figure 4.3: Percentage inhibition of α-amylase activity by crude aqueous, 
polysaccharide, methanol and dichloromethane extracts at 25 mg/ml. (AE= aqueous 
extract, PE= polysaccharide extract, ME= methanol extract, DCME= dicholoromethane 
extract) 
 
Values were expressed as mean ± SEM of three replicate determinations. Mean values 
with different lower case letters (a-d) indicate significant difference at p < 0.05. 
*Acarbose was used as negative control with the concentration at 25 µg/ml. 
 
Figure 4.4: Inhibition of α-amylase activity by F10-F100 protein fraction with acarbose 
at 25 µg/ml. 
 
Values were expressed as mean ± SEM of three replicate determinations. Mean values 
with different lower case letters (a-e) indicate significant difference at p < 0.05. 
*Acarbose was used as negative control with the concentration at 25 µg/ml. 
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4.4 Profiling of Seleted Active Protein Fractions by Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) Analysis 
 Protein profile for selected active protein fractions (F30 and F100) that inhibited 
α-glucosidase and α-amylase respectively were resolved and captured on 16% SDS 
polyacrylamide gel image as in Figure 4.5. Based on the image, F30 protein fraction (α-
glucosidase inhibitor) showed the presence of 10 protein bands (Lane 2) with molecular 
weight ranged approximately 5-70 kDa. Whereas F100 protein fraction (α-amylase 
inhibitor) showed the presence of nine protein bands ranged approximately from 6 kDa 
to 70 kDa. 
 From this SDS-PAGE analysis, the two selected anti-diabetic inhibitors F30 and 
F100 protein fractions showed a very distinct band profile, thereby was further 
fractionated by RP-HPLC. 
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                                                  Lane 1      Lane 2     Lane 3 
 
 
 
 
 
 
 
 
 
 
                                                   
 
Figure 4.5: Coomassie Brilliant Blue-stained 16% SDS-PAGE protein profile of P. 
pulmonarius F30 and F100 protein fractions 
 
The SDS-PAGE gel was stained by Coomassie Brilliant Blue. Lane 1: Pre-Stained 
SDS-PAGE standards protein marker. Lane 2: F30 protein fraction in sample buffer 
with DTT. Lane 3: F100 fraction protein in sample buffer with DTT. 
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4.5 Purification of Active Protein Fractions by Reversed-phase High Performance 
Liquid Chromatography (RP-HPLC) 
 Both active fractions with anti-diabetic potential, which were F30 protein 
fraction α-glucosidase inhibitor, and F100 protein fraction α-amylase inhibitor, were 
further fractionated by RP-HPLC. 
 
4.5.1 Purification Profile of F30 fraction separated by RP-HPLC 
 The selected protein fraction, F30 with α-glucosidase inhibitory activity was 
injected into HPLC column. The peaks obtained were referred as RP-HPLC fractions 
(RPF). The peaks and its retention times at 220 nm were shown in the chromatogram in 
Figure 4.6. Ten major peaks representing RPF identified in the chromatogram with its 
retention times (Rt) were listed in Table 4.3. 
 
4.5.1.1 Alpha Glucosidase Inhibitory Activity of F30 Fractions Separated by RP-
HPLC  
 Alpha glucosidase inhibitory assay was conducted to evaluate the RPF. All 
collected peaks evaluated showed α-glucosidase inhibitory activities (Figure 4.7) even 
though the concentration has been reduced by 10 times lower (2.5 µg/ml) compared to 
its actual sample concentration before purification by RP-HPLC. 
 Among all the RPF, at 2.5 µg/ml protein concentration, peak 3-RPF strongly 
suppressed the activity of α-glucosidase enzymes (25%) followed by peak 4-RPF and 
peak 8-RPF with same percentage of inhibition of 22% (Table 4.4). 
 All peaks of RPF appeared to be better inhibitors of α-glucosidase enzymes 
compared to voglibose. Peak 3-RPF shows a significant anti-diabetic activity and was 
chosen as the best candidate for further characterization using MALDI-TOF/TOF MS 
analysis.
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Figure 4.6: HPLC profile of F30 protein fraction 
 
Chromatogram for determination of protein profile for F30 fraction according to optimized method by column Chromolith SemiPrep RP-18 endcapped 
100-10 mm; flow rate 1 ml/min, at sample concentration of 2 mg/ml and detection wavelength of 220 nm. 
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Table 4.3: Retention times (Rt) at 220 nm for all RPF peaks from F30 protein fraction 
 
 
 
 
 
 
 
 
 
 
Table 4.4: Percentage of α-glucosidase inhibition of all RPF peaks from F30 protein 
fraction at 2.5 µg/ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RPF Peaks Retention time at 220 nm  
Peak 1 3.418 
Peak 2 3.633 
Peak 3 4.362 
Peak 4 5.094 
Peak 5 9.494 
Peak 6 10.014 
Peak 7 11.460 
Peak 8 12.079 
Peak 9 16.893 
Peak 10 23.804 
RPF Peaks % Inhibition of  α-glucosidase inhibitory assay 
Voglibose 13±2.03 
Peak 1 17±0.70 
Peak 2 18±1.11 
Peak 3 25±2.57 
Peak 4 22±2.99 
Peak 5 17±0.98 
Peak 6 19±2.37 
Peak 7 14±0.72 
Peak 8 22±2.07 
Peak 9 18±1.20 
Peak10 17±1.17 
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Figure 4.7: Inhibition of α-glucosidase enzyme activity by all protein fractions (RPF) 
from F30 at 25 µg/ml 
 
Mean values with different lower case letters (a-d) indicate significant difference at p < 
0.05.  
*Voglibose was used as negative control with the concentration 25 µg/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
a,b b 
d 
c 
a,b b 
a 
c 
b a,b 
0 
5 
10 
15 
20 
25 
30 
%
 In
hi
bi
tio
n 
 
 66 
4.5.2 Purification profile of F100 fractions separated by RP-HPLC 
 The selected protein fraction, F100 with α-amylase inhibitory activity was 
injected into HPLC column. The peaks obtained were referred as reversed-phase HPLC 
fractions (RPF). The peaks and its retention times at 220 nm were obtained as shown in 
the chromatogram in Figure 4.8. Six major peaks representing RPF identified in the 
chromatogram with its retention times (Rt) were listed in Table 4.5. 
 
4.5.2.1. Alpha Amylase Inhibitory Assay of F100 Fraction Separated by RP-HPLC  
 Alpha amylase inhibitory assay was conducted to evaluate the active fractions. 
All peaks collected showed α-amylase inhibitory activities even though the 
concentration has been reduced 4 times lower (6.25 µg/ml) compared to its actual 
sample concentration before purification by HPLC. 
 Among all the RP-HPLC fractions (RPF) (Figure 4.9), at 6.25 µg/ml protein 
concentration, peak 3-RPF showed the highest activity of α-amylase but with very low 
percentage of inhibition (2.84%) followed by peak 5-RPF and peak 4-RPF with 
percentage of inhibition, 1.45% and 1.1% respectively. There was no inhibition activity 
observed for peak 1-RPF and peak 2-RPF of RP-HPLC fractions (Table 4.6). Moreover, 
only peak 3-RPF appeared to be better inhibitors of α-amylase enzymes than a known 
acarbose. 
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Figure 4.8: HPLC profile of F100 protein fraction 
Chromatogram for determination of protein profile for F100 RPF according to optimized method by column Chromolith SemiPrep RP-18 endcapped 
100-10 mm; flow rate 1 ml/min, at sample concentration of 2 mg/ml and detection wavelength of 220 nm. 
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Table 4.5: Retention times (Rt) at 220 nm for all RPF peaks from F100 protein fraction
  
 
 
 
 
 
 
 
 
Table 4.6: Percentage of α-amylase inhibition of all RPF peaks from F100 protein 
fraction at 6.25 µg/ml 
 
 
 
 
 
 
 
 
 
RPF Peaks  Retention time at 220 nm 
Peak 1 3.625 
Peak 2 4.198 
Peak 3 5.137 
Peak 4 12.746 
Peak 5 17.590 
Peak 6 23.369 
RPF Peaks % Inhibition of  α-amylase inhibitory assay 
Acarbose 2.10±0.41 
Peak 1 0 
Peak 2 0 
Peak 3 2.85±0.36 
Peak 4 1.11±0.25 
Peak 5 1.44±0.23 
Peak 6 0.11±0.25 
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Figure 4.9: Inhibition of α-amylase enzyme activity by all protein fraction (RPF) from 
F100 at 6.25 µg/ml 
 
Mean values with different lower case letters (a-d) indicate significant difference at p < 
0.05.  
*Acarbose was used as negative control with the concentration 25 µg/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
c d 
d 
-0.5 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
Acarbose Peak 1 Peak 2 Peak 3 Peak 4 Peak 5 Peak 6 
%
 In
hi
bi
tio
n 
 70 
4.5.2.2   Evaluation of Synergism of Peak 3-RPF from F100 Fractions for Alpha 
 Amylase Inhibitor 
 For α-amylase inhibitor, only peak 3-RPF from F100 protein fraction showed 
inhibition result. Due to low percentage, the sample was subjected for a synergism 
mechanism study. Alpha amylase inhibitory assay was run at the 6.25 µg/ml for pre-
purified (F100 protein fraction) and post-purified fractions (Peak3-RPF) by HPLC. 
Percentage of inhibition for F100 protein fraction pre-purified was 12% and 2.85% for 
sample post-purified RP-HPLC (Peak 3- RPF) shown in Figure 4.10. Hence, because of 
the very low percentage of inhibition after purified by HPLC, peak 3-RPF from α-
amylase inhibitor was not chosen for further characterization using MALDI-TOF/TOF 
mass spectrometry analysis. 
 
4.6 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Profile of Peak 3-RPF of Alpha Glucosidase Enzyme Inhibitor 
The active peak 3-RPF from F30 protein fraction as α-glucosidase enzyme 
inhibitor was further resolved using SDS-PAGE thereby silver-stained 
electrophoregram was obtained (Figure 4.11). Lane 1 was a pre-stained SDS-PAGE 
standard protein marker and Lane 2 was an active peak 3-RPF.  
SDS-PAGE profile of the active peak 3-RPF showed the presence of five 
distinct protein bands (Table 4.7). From the SDS-PAGE gel, the bands were excised and 
prepared to further identification by MALDI-TOF/TOF MS analysis.  
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Figure 4.10: Inhibition of α-amylase enzyme activity for pre and post-purified by 
HPLC and at 6.25 µg/ml  
 
Pre-purified was F100 protein fraction and post-purified was Peak 3-RPF by RP-HPLC 
purification. Mean values with different lower case letters (a-c) indicate significant 
difference at p < 0.05. 
*Acarbose was used as negative control with the concentration 6.25 µg/ml. 
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       Lane 1   Lane 2 
Figure 4.11: Silver-stained electrophoregram of active peak 3-RPF (α-glucosidase 
inhibitor 
 
 
Peak 3-RPF showing several different protein bands. The SDS gel was stained with 
silver staining (MS compatible). Lane 1: Pre-stained SDS-PAGE standards protein 
marker. Lane 2: Active peak 3 reversed-phase fraction (RPF) 
 
 
Table 4.7: SDS-PAGE gel protein bands with approximate molecular weight 
 
 
 
 
 
 
 
Band in SDS-PAGE Gel ~Molecular Weight 
Band 1 250 kDa 
Band 2 116 kDa 
Band 3 66 kDa 
Band 4 45 kDa 
Band 5 20 kDa 
205 kDa 
116 kDa 
66 kDa 
45 kDa 
29 kDa 
20 kDa 
14.2 kDa 
6.5 kDa 
Band 2 (116 
 
Band 1 (250 
 
 
Band 3 (66 kDa) 
 
Band 4 (45 kDa) 
 
Band 5 (20 kDa) 
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4.7 Identification of Anti-diabetic Related Proteins by MALDI-TOF/TOF Mass 
Spectrometry Analysis  
 In this experiment, two protocols of MALDI-TOF/TOF MS (In-gel and In-
solution digestions) were used to identify protein and the results were compared. For 
proteins which were collected into fractions and then subjected to protein analysis (in-
solution digestion), they could be directly characterized meanwhile SDS-PAGE gel 
plugs were excised is necessary to recover the protein from the gel (in-gel digestion). 
 
4.7.1 MALDI-TOF/TOF MS Analysis of Five Protein Bands Obtained From Peak 
3-RPF/F30 Silver-Stained Electrophoregram by In-Gel Digestion Protocol 
 From the protein bands observed by SDS-PAGE gel profile from 
electrophoregram (Figure 4.11), the 5 proteins band indicated with arrows were excised, 
in-gel digested and analysed by MALDI-TOF/TOF MS analysis.  
 Several available protein databases were used such as All Swissprot, Fungi 
National Center for Biotechnology Information (NCBI), Fungi Swissprot, Lentinus 
NCBI and Lentinus Swissprot. Among all databases used, only proteins obtained using 
the Lentinus NCBI showed the relationship with diabetes. The name of the protein, 
molecular weight, protein score and accession number of identified proteins (band 1-5) 
(Appendix D (1.0)) from the Lentinus NCBI database were listed in simplified form in 
Table 4.8. 
 According to the protein score from the MALDI-TOF/TOF analysis (Table 4.8), 
Lentinus NCBI database represented 10 identified proteins. Three proteins were 
suggested to be related to diabetes (based on their function). The proteins are trehalose 
phosphorylase (84 kDa), followed by glyceraldehyde-3-phosphate dehydrogenase and 
catalase (43 kDa) (Table 4.9). These three proteins have been reported to have 
properties that indirectly inhibit diabetes and diabetic-related complication pathways. 
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However, the anti-diabetic mechanism of action of these proteins may be different from 
each other. 
 
4.7.2  MALDI-TOF/TOF MS Analysis of Peak 3-RPF by Using In-Solution 
Digestion Protocol 
 The peak of RPF fraction that showed the best percentage of α-glucosidase 
inhibition (Peak 3-RPF) was chosen for further characterization using MALDI-
TOF/TOF MS analysis. Ten most significant proteins with its molecular masses were 
listed in Table 4.10. 
 The data was obtained by using Mascot searching database. The top score was 
42 for PROF1_PHAVU, Profilin-1-Phaseolus vulgaris (Kidney Bean) but it is not 
significant according to Mascot however, from the record and previous research, 
profilin protein has a function to inhibit anti-diabetic indirectly. Mascot database 
software (Matrix Science Ltd, London, UK) (Aminudin et al., 2008) reports a match as 
significant if it has a match with a less than 5% chance of being a random hit (Appendix 
D (2.0)) 
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Table 4.8: List of matched identified proteins based on Lentinus NCBI database 
 
Band 
ID Name of the Protein 
Accession number 
NCBI 
Protein 
score 
Protein Molecular 
Weight (Da) 
Protein 
PI 
No. Of 
Peptide Match 
Band 1   
1 Trehalose phosphorylase gi/74626081 18 83999.8 6.38 4 
2 Glyceraldehyde-3-phosphate 
dehydrogenase 
gi/30580405 11 36 156.7 6 3 
3 HSP 100 gi/62998570 9 99 394 5.71 6 
4 WUN [L. sajor-caju] gi/6018116 8 5174.7 10.43 1 
5 RNA polymerase II second largest subunit  gi/194306409 7 33 383 8.34 3 
6 Antimicrobial ribonuclease gi/71153693 6 1015.5 6.13 1 
7 Heat-induced catalase [L. sajor-caju] gi/13183346 5 60 039 6.77 2 
8 laccase 3 [L. sajor-caju] gi/11036960 5 18 143.7 5.23 1 
9 Translation elongation factor 1 alpha gi/170517001 4 20 207.6 7.07 1 
Band 2   
1 HSP100 [L. sajor-caju] gi/62998570 14 99 394 5.71 4 
2 Glyceraldehyde-3-phosphate 
dehydrogenase 
gi/30580405 13 36 156.7 6 2 
3 RNA polymerase II second largest subunit gi/194306409 6 33 383 8.34 1 
4 Catalase [L. sajor-caju] gi/28558774 5 43 768.6 6.19 1 
5 Heat-induced catalase [L. sajor-caju] gi/13183346 5 60 039 6.77 1 
6 Trehalose phosphorylase gi/74626081 4 83 999.8 6.38 1 
Band 3   
1 RNA polymerase II second largest subunit gi/194306409 8 33 383 8.34 1 
2 Glyceraldehyde-3-phosphate 
dehydrogenase 
gi/30580405 8 36 156.7 6 1 
3 Trehalose phosphorylase gi/74626081 8 83 999.8 6.38 1 
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Table 4.8, continued. 
 
Band 
ID Name of the Protein 
Accession number 
NCBI 
Protein 
score 
Protein Molecular 
Weight (Da) 
Protein 
PI 
No. of Peptide 
Match 
4 Catalase [L. sajor-caju] gi/28558774 7 43 768.6 6.19 1 
5 HSP100 [L. sajor-caju] gi/62998570 7 99 394 5.71 2 
6 Heat-induced catalase [L. sajor-caju] gi/13183346 6 60 039 6.77 3 
Band 4   
1 Trehalose phosphorylase gi/74626081 32 83 999.8 6.38 1 
2 Glyceraldehyde-3-phosphate 
dehydrogenase 
gi/30580405 11 36 156.7 6 2 
3 HSP100 [L. sajor-caju] gi/62998570 10 99 394 5.71 3 
4 RNA polymerase II second largest subunit 
[L. sajor caju] 
gi/194306409 8 33 383 8.43 2 
5 laccase 4 [L. sajor-caju] gi/11036962 5 18 143.7 4.92 1 
6 Catalase [L. sajor-caju] gi/28558774 5 43 768.6 6.19 1 
7 Heat-induced catalase [L. sajor-caju] gi/13183346 4 60 039 6.77 1 
Band 5   
1 Trehalose phosphorylase gi/74626081 18 83 999.8 6.38 5 
2 RNA polymerase II second largest subunit  gi/194306409 12 33 383 8.34 4 
3 Heat-induced catalase [L. sajor-caju] gi/13183346 10 60 039 6.77 4 
4 Glyceraldehyde-3-phosphate  
dehydrogenase 
gi/30580405 10 36 156.7 6 3 
5 HSP100 [L. sajor-caju] gi/62998570 10 99 394 5.71 7 
6 Catalase [L. sajor-caju] gi/28558774 9 43 768.6 6.19 3 
7 WUN [L. sajor-caju] gi/6018116 8 5174.7 10.43 1 
8 Translation elongation factor 1 alpha [L. 
sajor-caju] 
gi/170517001 4 20207.6 7.07 1 
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Table 4.9: Potential proteins obtained from Lentinus NCBI database (In-gel digestion 
MALDI-TOF/TOF) which are indirectly related to anti-diabetic mechanisms 
 
 
 
 
 
 
 
 
Table 4.10: Ten abundant proteins identified of Peak 3-RPF from Mascot database (In-
solution digestion MALDI-TOF/TOF) 
 
 Accession Mass 
(Da) 
Score Name of Protein No. Of 
Peptide 
Match 
1 PROF1_PHAVU 14 172 42 Profilin-1- Phaseolus 
vulgaris (Kidney Bean) 
(French bean) 
2 
2 PROF1_RICCO 14 199 42 Profilin_1- Ricinus 
communis (Castor bean) 
2 
3 PROF1_SOYBN 14 091 42 Profilin-1- (GmPRO1) 
(Allergen Gly)- Glycine 
max (Soybean) 
2 
4 PROF2_HEVBR 14 142 42 (Pollen allergen Hev b)- 
Hevea brasiliensis 
2 
5 PROF2_MALDO 14 043 42 Pollen allergen Mal d- 
Malus domestica (apple) 
2 
6 PROF2_SOYBN 14 091 42 Profilin-1- (GmPRO1) 
(Allergen Gly)- Glycine 
max (Soybean) 
2 
7 PROF_FRAAN 14 058 42 Profilin (Allergen Fra a 
4)- Fragaria ananassa 
(strawberry) 
2 
8 PROF_PRUPE 13 980 42 Profilin (Allergan Pru p 
4.02)- Prunus persica 
(Peach) 
2 
9 EX7S_GEOSL 8693 38 Exodeoxyribonuclease 7 
small subunit 
2 
10 Y1491_LACJO 18 213 37 UPF0090 protein 
LJ_1491- Lactobacillus 
johnsonii 
2 
 
 
Anti-diabetic related protein Protein Molecular 
Weight (Da) 
Protein 
Band 
Protein 
Score 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
36, 000 2 13 
Catalase 43, 000 5 9 
Trehalose Phosphorylase 84, 000 4 32 
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5.0 DISCUSSION 
 Pleurotus pulmonarius basidiocarps was extracted by several methods of 
extractions including distilled water, methanol, dichloromethane and ethanol to yield 
the aqueous, methanol, dicholoromethane and polysaccharide extracts. Most solvent 
extracts, crude and protein fractions of P. pulmonarius basidiocarps demonstrated the in 
vitro anti-diabetic activity based on two assays involving carbohydrate metabolizing 
enzymes; α-glucosidase and α-amylase. The inhibition of these enzymes, which are 
involved in the digestion of carbohydrates, can significantly reduce postprandial 
elevations of blood glucose and therefore offers an alternative strategy in the 
management of blood glucose level especially in type 2 DM (Codario, 2011).  
 Aqueous extracts showed the highest yield percentage (18.34 %) compared to 
other extraction methods. Extract yield differences might be due to the different 
availability of extractable components in the extracts resulting from the varied chemical 
composition (Sultana et al., 2009). Furthermore, different extraction methods were used 
because Pleurotus genus possibly produce various range of bioactive as a 
pharmacological compounds such as pigments, aromas, organic acids, polysaccharides, 
enzymes, vitamins and amino acid (Dalonso et al., 2010). 
 In this study, protein fractions of P. pulmonarius basidiocarps were shown to 
exhibit potent anti-diabetic inhibitory activity in vitro. It has been reported that aqueous 
extracts of P. pulmonarius have hypoglycemic effects and when interact with oral anti-
diabetic agents such as glyburide, acarbose and rosiglitazone it could monitor on serum 
glucose level (Badole et al., 2006; Badole et al., 2007; Badole et al., 2008). According 
to Kanagasabapathy et al., (2013), P. pulmonarius contains low fat and high soluble 
fiber content, with no starch and low sugar. Additionally, it also have gastronomic, 
nutritional and medicinal properties besides easily cultivated on a large range of 
substrates. 
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 Salting out method using ammonium sulphate to precipitate water soluble 
protein from aqueous extracts was used as early step purification resulted with the 
formation of 10 protein fractions (F10-F100). Proteins are soluble in water due to their 
interaction with hydrophilic amino acid side-chains facing outwards. Ammonium 
sulphate interferes these interactions between amino acids side-chains and water by 
reducing the available water thus reduce the solubility of protein, and hence, the protein 
will precipitate out from the solution. Low temperature is required throughout the 
experiment (4 oC) to ensure protein is not denatured. Different proteins precipitate at 
different concentrations of ammonium sulphate (Komsta et al., 2011). 
 Twenty-five mg/ml of four crude organic extracts with 25 µg/ml protein content 
of F10-F100 protein fraction were assayed for anti-diabetic inhibitory assays. A higher  
concentration of solvent extract were used because there are severeal compounds mix 
together and the active compound could only composed a minor protein. Therefore, a 
higher amount are needed compared to the protein since there are considered to be 
purified protein from crude extract. Among all the solvent extracts, aqueous extract and 
protein fractions, F30 strongly suppressed the activity of α-glucosidase enzyme 
(24.18%). Meanwhile F100 protein fraction for inhibitory activity of α-amylase enzyme 
(41.80%). Methanol, dichloromethane and polysaccharide extracts showed very low 
inhibition percentage although the concentration used was 10-fold higher. According to 
Jarald et al., (2008), aqueous extract and non-polysaccharide fraction of the plant 
reported can decrease the serum glucose level and other complications in alloxan 
diabetic animals.  
 Based on the results, it could be hypothesized that these proteins have different 
hydrophobic strength with F30 protein fraction being more hydrophobic meanwhile 
F100 protein fraction is very much hydrophilic (Scopes, 1994). In order to demonstrate 
synergism between the protein fractions, a lower concentration of each fractions were 
 80 
mixed and re-evaluated. If the mixture gave an effect higher than individual protein 
fraction, this suggests than both fractions are required and thus prove synergustic 
relationship. Hydrophobicity (and hydrophilicity) had been shown to have a major role 
in the binding behaviour of specific drugs and proteins. This can be explained by the 
enzymes work at the different places in human intestinal tract and with different 
mechanisms of action therefore, the hydrophobicity which explaining the binding 
behaviour of certain drugs also may differ (Seedher & Kanojia, 2008). According to 
Melander, (2004) the hydrophobicity characteristic explains the differences in clinical 
efficacy or safety therapeutic drugs even though it shows identical mechanisms of 
action. As an example for anti-diabetic drugs, sulfonylureas, phenformin and adenosine 
monophosphate-activated protein kinase (AMPK) are hydrophobic (Gruzman et al., 
2009) meanwhile metformin is hydrophilic (Viollet et al., 2012).  
 As displayed in Figure 4.5, SDS-PAGE analysis of the selected F30 protein 
fraction for α-glucosidase inhibitor (10 bands) and F100 protein fraction α-amylase 
inhibitor (9 bands) demonstrated a very distinct band profile; hence, was further 
fractionated by RP-HPLC. Distinct RPF peaks from the fraction were then collected and 
furthered re-evaluated with the same assays. Based on the assays, peak 3-RPF from F30 
protein fraction, exerted strong inhibitory activity (25%) towards α-glucosidase enzyme 
meanwhile peak 3-RPF from F100 protein fraction only demonstrated 2.84% inhibition 
towards α-amylase enzyme. The result indicated a possible synergistic interaction 
between proteins in F100 protein fraction since they effectively inhibited α-amylase 
inhibitory activity when present together but the inhibition effect became insignificant 
once they were separated through RP-HPLC (Oikonomakos et al., 2002; Thompson & 
Orvig, 2006). 
 Semi pure fraction represented by peak 3-RPF from F30 protein fraction was 
subjected to SDS-PAGE and visualised using compatible silver staining prior to in-gel 
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digestion for MALDI-TOF/TOF-MS analysis. Mass spectrometry analysis against 
Lentinus NCBI database revealed three possible proteins that have a direct/indirect 
relation with the prevention of DM which are glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), catalase and trehalose phosphorylase. Lentinus NCBI was 
selected in detecting proteins because it is the nearest genus. Since many fungi database 
are still largely incomplete, many proteins present in P. pulmonarius are absent in those 
databases. This also explain the low score for all proteins obtained. 
 On the other hand, for in-solution MALDI-TOF/TOF-MS, profilin is the most 
abundant proteins detected via Mascot database search. It may have a potential 
mechanism in inhibiting diabetic. We hypothesized that profilin was present in high 
abundance in the fraction and thus, easily identified. Due to its small molecular weight, 
it could be possible that it diffuses out from the SDS-PAGE gel, and therefore, not 
identified via in-gel digestion MALDI-TOF/TOF-MS. 
 All four proteins which were profilin, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), catalase and trehalose phosphorylase involved in the 
regulation of blood glucose level through various mechanisms based on its ability to 
inhibit antidiabetic activity in vitro. Profilin (14 kDa) is ubiquitous small proteins that is 
commonly found in mammals, animal cells, plants, and viruses (Witke et al., 2001). 
Profilin is also essential for sustainability of eukaryotes ranging from fungi to animals 
(Vidali et al., 2007). Profilin-2 is predominantly expressed at lower levels in neuronal 
cells, skeletal muscle, uterus and kidney (Geese et al., 2000).  
 Profilin binds to actin and affects the structure of the cytoskeleton. At high 
concentration, profilin prevents the polymerization of actin, whereas it enhances it at 
low concentration (Saarikangas et al., 2010). Furthermore, profilin also acts as a tumour 
suppressor molecule for breast cancer cells and has a potential to inhibit metastasis 
(Krishnan & Moens, 2009). Deletion of profilin genes will give rise to Miller-Dieker 
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syndrome, a genetic disorder (Kullmann et al., 2012). On  another account, profilin is a 
signalling molecule involved in the binding of phosphatidylinositol 4,5-bisphosphate 
(PIP2), which means it also indirectly involve in the regulation of diabetes metabolism 
or biomolecules. 
 In human, activation of protein kinase C (PKC) contributes to hyperglycemia 
induced cell damage. Activation of the PKC pathway through the de novo synthesis of 
diacylglycerol (DAG) from glycolytic intermediates could results with complication of 
DM. It is also associated with neurovascular changes, insulin resistance and many 
vascular abnormalities in the retinal, renal, neural and cardiovascular tissue. Therefore, 
PKC may have vital role in the cardiovascular diseases (Geraldes & King, 2010). 
 PKC requires its activator, DAG and calcium for activation (Chu & Silverstein, 
2012). In DAG-PKC mechanism, PIP2 is hydrolysed by phospholipase C (PLC) into 
two intracellular signalling molecules, inositol trisphosphate (IP3) and DAG. This will 
increase intracellular calcium available (Pintérová et al., 2011). PKC activation occurs 
with binding of DAG, in the presence of calcium ions (Ca2+) resulting in translocation 
of the PKC-DAG complex to the cell membrane (Zuzek et al., 2013). IP3 opens calcium 
channel to allow calcium entry from the endoplasmic reticulum and extracellular fluid. 
PIP2 is the precursor of two-second messengers, inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG), which regulate a variety of cellular processes meanwhile DAG 
major function is to activate the PKC (Hille, 2012). 
 Activation of PKC induced by glucose increases production of extracellular 
matrix and cytokines which leads to enhance contractility, permeability and vascular 
cell proliferation. Oxidants such as hydrogen peroxide (HP) can also contribute to PKC 
activation either directly or by increasing DAG production (Nishikawa et al., 2000). 
 In diabetic, the augmented availability of glucose caused an augmented 
availability of DAG through de novo synthesis and consequent activation of PKC. 
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Effect of this extra activation is different and detrimental for vascular functionality 
because it increase vascular permeability (Piconi et al., 2007). In addition, the 
secondary metabolic products such as reactive oxygen intermediates, oxidative stress, 
fatty acid and advanced glycation end products (AGEs) can also activate PKC 
independently of DAG (Rains & Jain, 2011).  
 From the previous research, profilin has been discussed as a negative regulator 
of the PLC activity in DAG-PKC pathway (Goldschmidt-Clermont et al., 1990). 
Profilin binds with high affinity to small clusters of PIP2 molecules in micelles and also 
in bilayers with other phospholipids. In the case of profilin and actin, it has been 
assumed that PIP2 binds to the profilin. By binding to PIP2, it interferes and lowers rate 
of PIP2 hydrolysis by soluble PLC and consequently inhibits the formation of IP3 and 
DAG. PIP2-profilin complex is a poor substrate for PLC (Elnakish & Hassanain, 2012).  
 Profilin competes efficiently with platelet cytosolic phosphoinositide-specific 
PLC for interaction with the PIP2 substrate and thereby inhibits PIP2 hydrolysis. Profilin 
is an effective inhibitor of PIP2 hydrolysis by PLC, even when the concentration of 
calcium ion (Ca2+) is optimal for PLC activity. The low Ca2+ concentration together 
with profilin should reduce the further activity of PLC (Kang & Othmer, 2007). 
 Thus, it could be possible to suggest that profilin might play a critical role and 
may represent a new therapeutic target to prevent various disease pathogenesis and as a 
mediator in diabetic vascular injury (Caglayan et al., 2010). However, more studies 
need to be done in order to fully understand the profilin-signalling pathway and its 
mechanism of regulation. Drug development in this area is necessary as it may offer 
therapeutic options for diabetic complications, cancer, autoimmune disease and 
inflammation (Skvortsova, 2013). 
 The second protein identified is GAPDH enzyme (~37 kDa), responsible to 
catalyzes the reaction of glyceraldehyde-3-phosphate (GAP) conversion to 1,3 
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diphosphoglycerate (Tatton et al.,  2000). GAPDH provides a common link between 
hyperglycemia-induced, oxidative stress and activation of some major pathways 
associated with the pathogenesis of diabetic complications. Madsen-Bouters et al., 
(2010) reported that GAPDH acts as a mediator in the activation of pathways implicated 
in the pathogenesis of diabetic retinopathy. 
 GAPDH functions actively to regulate the insulin pathway. The segregation of 
GAPDH releases the suppressor of insulin signaling from the cell membrane, and thus 
activates the insulin signaling (Devitt, 2006). Min et al., (2006) also suggested that 
GAPDH is an active regulator in the phosphoinositide-mediated signaling pathway and 
a potential new target for insulin resistance treatment which eventually help to treat 
diabetes. 
 However, GAPDH activity and abundancy are significantly perturbed in DM 
because it is exquisitely sensitive to modification by cellular processes. It occurs 
because the enzyme contains a highly reactive thiol at its active site which is sensitive to 
modification by a variety of compounds such as reactive aldehydes, glycating agents 
and oxidative radicals (Schuppe et al., 1994). Recently, this perturbations in GAPDH 
have been connected to cellular dysfunction in several neurodegenerative diseases 
(Chuang et al., 2005). 
 Inhibition of GAPDH  involves the formation of methylglyxol (MG), AGEs, 
activation of PKC, induction of the hexosamine and polyol pathways; which eventually 
contribute to the development of diabetic complications (Beisswenger et al., 2003; 
Brownlee, 2005). GAPDH increases AGEs formation by increasing MG and activates 
PKC by the formation of DAG. Furthermore, toxic potential of MG has effects on 
insulin secretion from pancreatic beta cells (Ulrich & Cerami, 2001). Decrease GAPDH 
activity may also play a role in the high rates of artherosclerosis associated with 
diabetes and the insulin resistance syndrome (Leyva, 1998).  
 85 
 Structural mutations of the GAPDH gene and altered gene expression could lead 
to significantly altered function and increased triose phosphate and MG production in 
response to hyperglycemia (Nemet et al., 2006). Thus, GAPDH is suggested to control 
a crucial metabolic step that determines the levels of MG precursor and can therefore 
regulate its production. 
 In hyperglycemia, AGEs glycate with protein, making it saturated and results in 
loss of function and poor gene expression. AGEs modulate the initiating steps in 
atherogenesis involving blood-vessel wall interactions, cause plaque formation and 
block the blood vessel. This will leads to high blood pressure, atherosclerosis, 
amputation, cataracts, and attract bacterial attachment to unavoidable injuries or cuts 
(Aronson & Rayfield, 2002). It also could lead to neuropathological changes in the 
brain and the subsequent behavioural deficits; characteristics of autism (Maher, 2012).  
 Both MG and AGEs are able to induce oxidative stress, inflammation and 
mitochondrial dysfunction, which implicated in diabetic complications and multiple 
neurological diseases. Therefore, researchers are trying to develop various 
pharmacological approaches in order to avoid deleterious effects of AGEs reactions. It 
has been postulated that environmental factors or genetic dysregulation can modify 
GAPDH production consequent effects in MG production and AGEs production 
(Beisswenger et al., 2003).  
 Besides, GAPDH gene expression can be regulated by hormonal, nutritional and 
metabolic factors including insulin, which can increase GAPDH mRNA and activity up 
to 10 fold in liver and fat cells. Thus when GAPDH is higher, none of MG and AGEs 
will be produced. The discovery of GAPDH adds another target that can be addressed in 
combating the disease (Jagt, 2008). 
 The third possible protein is trehalose phosphorylase (TP), which is widely 
distributed in many microorganisms, plants, and animals such as in bacteria, fungi, 
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yeast, insects, nematodes, shrimp and invertebrate animals (Elbein et al., 2003). This 
enzyme also has been found in mushrooms such as Flammulina velutipes, Pichia 
fermentans, Euglena gracilis, cyanobacterial Scytonema species (Inoue et al., 2002), 
Grifola frondosa (Saito et al., 1998), Agaricus bisporus (Wannet et al., 1998), 
Catellatospora ferruginea (Aisaka et al., 1998) and Pleurotus ostreatus (Schwarz et al., 
2007).   
 TP participates in starch, sucrose and glycogen metabolism and also plays a vital 
role especially in trehalose metabolism (Ng, 2004). Its function is to catalyzes the 
phosphorylase of trehalose into α-glucose-1-phosphate (α-Glc-1-P) and glucose and the 
reaction is reversibly. According to  Eis & Nidetzky (1999), the equilibrium of the 
reaction lies in the direction of trehalose synthesis. However, since the reaction was 
ditermined in vitro, there is uncertainty about the participation of TP in the synthesis or 
degradation of trehalose in vitro (Avonce et al., 2006).  
 Trehalose (α, α-1, 1-glucosyl-glucose) is a non-reducing disaccharide of d-
glucose in which the two glucoses are linked in a α, α-1, 1-glycosidic linkage. It is a 
common sugar, concentrations that can exceed significantly those of other storage 
carbohydrate such as glycogen and found in vegetative cells, spores of fungi and 
mushrooms which contain up to 10–25% by dry weight (Elbein et al., 2003). Trehalose 
can play a number of different roles in biological systems, such as serving as a reservoir 
of glucose for energy or carbon, functioning as a stabilizer or protectant of proteins and 
membranes during times of stress, acting as a regulatory molecule in the control of 
glucose metabolism, serving as a transcriptional regulator and playing a structural and 
functional role as a component of various cell wall glycolipids in mycobacteria and 
related organisms (Avonce et al., 2006). It may also act as a signalling or regulatory 
molecule in some cells and link trehalose metabolism to glucose transport and 
glycolysis (Elbein et al., 2003). 
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 Because of its ubiquitous role, trehalose is currently known as a component in 
food especially for DM patient because it can help to inhibit progression of type 2 DM. 
In 1995, the development of a large-scale biological procedure for commercial 
production of trehalose, enable the community to use trehalose as a component in foods 
and cosmetics (Arai et al., 2001). It is a natural sugar found in nature, easy to process, 
has a pleasant taste and have a potential to protect against metabolic syndrome. 
Trehalose will not trigger a rise in blood glucose levels, unlike other foods and drinks. 
Intake of trehalose has been shown to evoke lower insulin secretion and mitigates 
insulin resistance (Arai et al., 2010). Moreover, trehalose has a suppressive effects on 
osteoporosis development (Higashiyama, 2002). 
 There are several mechanisms that can increase the trehalose production and one 
of them involves a single enzyme TP that catalyses the interconversion of maltose and 
trehalose (Pan et al., 2004). This happens because TP control intracellular levels of 
trehalose by converting excess trehalose to maltose, which can then be converted by a-
glucosidases to glucose (Wolf et al., 2003). 
 Trehalose and TP are both involved in the production and degradation of 
glycogen, making both metabolisms of trehalose and glycogen interconnected. TP 
affects the levels of glycogen and utilization of trehalose in cells. For example, TP 
accumulates large amounts of glycogen when grown in high concentrations of trehalose, 
but mutants missing TP activity do not accumulate glycogen, regardless of the amount 
of trehalose in the media (Pan et al., 2008). TP acts as a sensor or regulator of trehalose 
levels in these cells by catalysing the conversion of glycogen to trehalose when 
cytoplasmic trehalose levels are low. TP enzyme also can expedite the conversion of 
trehalose to glycogen when cytoplasmic trehalose levels become high. Thus, TP 
represents another pathway for the production of trehalose from glycogen, involving 
maltose as an intermediate (Pan et al., 2008).  
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 TP is not only involved in the production of trehalose from glycogen, but also 
appears to play an essential role in the formation and accumulation of glycogen (Elbein 
et al., 2003). Thus it is good for diabetic patients to replace the intake of sugar (sucrose) 
with trehalose, since TP manage to control the level of trehalose in the body by 
changing it to glycogen and trehalose has been proven better than sucrose. Removal of 
excessive trehalose from the body is necessary because high levels of trehalose will 
cause toxic effect. Thus, it could be suggested that TP proteins found in by P. 
pulmonarius extracts can help to maintain the level of trehalose in diabetic patients and 
ensure a balanced glucose-glycogen metabolism. 
 The fourth possible protein is catalase enzyme (43 kDa), commonly found in 
nearly all organisms. In human, catalase could be found in high concentration in the 
human liver, kidney and erythrocytes but much lower in connective tissue, pancreas, 
brain and serum (Scandalios et al.,  1997). Almost 98% of blood catalase activity is 
localized in the erythrocytes (Lai, 2008). Catalase catalyses the breakdown of hydrogen 
peroxide (HP) into oxygen and water (Góth et al., 2001). An absence of catalase 
(acatalasemia) in human body resulted with the homozygous mutations of the gene 
prone to have links with DM, Alzheimer’s disease and tumours (Góth & Nagy, 2012). 
 Catalase acts as antioxidant, inhibits the oxidation of other molecules, helps 
enhance the insulin secretion and insulin sensitization (Lai, 2008). High free radicals 
and low antioxidant defence mechanism will damage of high lipid peroxidation, cellular 
organelles, enzyme and results insulin resistance (Prentki & Nolan, 2006).  
 Free radicals involved in oxidative stress and lead to the damage of pancreas 
(Xu et al., 1999). It also leads to retinopathy, neuropathy, nephropathy atherosclerosis, 
cataract and cardiopathy. In human tissues, catalase plays a primary role in controlling 
HP concentration, increase in response to oxidative stress and protect pancreatic beta 
cells from damage. Therefore catalase is important to inhibit the activity of free radicals 
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and avoid diabetic long term complications (Giacco & Brownlee, 2010). 
 Sartoretto et al., (2011) demonstrated deficiency of catalase may cause elevated 
HP concentration with both toxic and physiological effects. Prolonged high HP 
concentration leads to long-term oxidative stress and contribute to DM and its 
complication. Factors that decrease catalase level include catalase gene mutations, 
catalase enzyme inactivation, or downregulation (Hamada et al., 2004). 
 HP is a byproduct of normal respiration and also formed from superoxide anion 
by action of superoxide dismutase. Low level concentration of HP acts as a cellular 
messenger in insulin signalling while in an excessive concentration it may cause toxic to 
protein, RNA, DNA, lipids and usually damages pancreatic cells (which are catalase 
poor) and also inhibits insulin signalling (Barbosa et al.,  2013). It can be postulated that 
deficiency of this catalase might leads to cumulative oxidant damage and ultimately, 
failure of pancreatic beta cells and diabetes (Styskal et al., 2012).  
 The risk may be due to peroxide damage of normally catalase-poor pancreatic 
beta cells, which are sensitive to oxidation (Chen et al., 2001). This is because, one of 
the unique features of beta cells is their relative low expression of many oxidant 
enzymes but it is further lowered by acatalasemia mutations (Vitai & Góth, 1997). Beta 
cell susceptibility could increase to oxidative damage, cell death induced by HP. The 
damage by peroxide should depend on whether the low catalase effect is chronic or 
acute (Rains & Jain, 2011). 
 Diabetic patients are usually accompanied by increased production of free 
radicals or impaired antioxidant defences. In type 2 diabetic patient, the downregulation 
of catalase synthesis may cause decreased blood catalase activity which consequently 
increase the level of HP (Baynes & Thorpe, 1999). 
 In summary, catalase is highly beneficial to the organs and body processes 
because it has a substantial capacity for removing intra- and extracellular HP. Catalase 
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provide protection for tissues with low catalase activity because it has high turnover 
numbers; one molecule of catalase can decompose more than one million molecules of 
HP per second (Góth & Vitai, 2003). 
 It is necessary to take the right amount of minerals and proteins to sustain the 
sources of catalase in the body. For example the natural catalase sources are barley 
grass, fruits, vegetable and Aspergillus niger (Marsili et al., 2004; Bankar et al., 2009). 
Currently, treatment of antioxidant-based drug formulations which is due to catalase 
gene alterations by captopril, aminoguanidine, melatonin and acetylsalicylic acid are 
available but as discussed, drugs have negative side effects (Messner & Imlay, 2002). 
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6.0 CONCLUSION 
 Protein fractions from P. pulmonarius basidiocarps have significant potential 
inhibition towards α-glucosidase and α-amylase enzymes higher than crude aqueous, 
dichloromethane, methanol and polysaccharide extracts. The protein fractions were 
further separated via RP-HPLC and all the eluted peaks were collected and assayed for 
the antidiabetic activities. Based on SDS-PAGE analysis, the two selected fractions 
with anti-diabetic potentials (F30 and F100 protein fractions) showed a very distinct 
banding profile and thereby was further purified by second round of RP-HPLC. Among 
all the eluted sub-fraction peaks, peak 3 RPF from F30 showed an inhibition towards α-
glucosidase enzyme. F100 fraction showed low inhibition percentage probably because 
of synergistic interaction since they effectively inhibited α-amylase activity as a group 
but the inhibition effect became insignificant once they were separated through RP-
HPLC. Identification by MALDI-TOF/TOF-MS revealed the presence of promising 
anti-diabetic related proteins in these sub-fractions. 
 As a conclusion, we have characterized four potential inhibitors from Pleurotus 
pulmonarius basidiocarps, which could be useful in combating diabetic disease with 
reference to their ability to inhibit in vitro α-glucosidase activity. However, there is no 
significant activity of α-amylase in vitro inhibition observed. We claimed that the 
profilin-like, trehalose phosphorylase-like, gylceraldehyde-3-phosphate dehydrogenase-
like and catalase-like proteins might promote the lowering of glucose level in blood, 
reduce insulin resistance and prohibit the risk of cardiovascular diseases.  
 Based on this research, the consumption of P. pulmonarius should be promoted 
as it contains 4 types of proteins with very close relationship to diabetic and its 
complication issues. These proteins from P. pulmonarius could be further developed as 
alternative therapeutics for the treatment of DM as well as its complication and other 
carbohydrate mediated diseases. Any therapeutic peptide derived from an edible 
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mushrooms that can be eaten daily are potentially safer and may have lesser possibility 
to exert adverse side effects.  
 However, in order to determine the identity of the α-glucosidase inhibitor, 
further protein isolation is required. It is necessary to fully characterize this active 
principle, both structurally and functionally, to validate its role as potential anti-diabetic 
molecule. In vivo study using animal could be proposed to add assurance regarding the 
safety and efficacy of the new drug. 
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APPENDIX A: PREPARATION OF EXTRACTS AND REAGENTS 
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1.1 Preparation of Standard and Working Reagent for Pierce BCA Protein 
Assay Kit  
a. Preparation of Diluted Albumin (BSA) Standards 
 Table 1 was used as a guide to prepare a set of protein standards. The contents of 
the one Albumin Standard (BSA) ampule were diluted into several clean vials, 
preferably using the same diluent as the sample(s). Each 1 ml ampule of 2.0 mg/ml 
Albumin Standard is sufficient to prepare a set of diluted standard for either working 
range suggested in Table 1. There will be sufficient volume for three replications of 
each dilute standard. 
 
Table 1. Preparation of Diluted Albumin (BSA) Standards; Dilution Scheme for 
Standard Test Tube Protocol and Microplate Procedure (working range=20-2000 µg/ml) 
  
 
b.  Preparation of the BCA Working Reagent (WR) 
i. The following formula was used to determine the total volume of WR required: 
(# standards + # unknowns) x (# replicates) x (volume of WR per sample) = Total 
volume WR required  
Note: There is only 200 µl of the WR reagent required for each sample in the microplate 
procedure. 
Vial Volume of 
Diluent 
Volume and Source of 
BSA 
Final BSA 
Concentration 
A 0 300 µl of Stock 2000 µg/ml 
B 125 µl 375 µl of Stock 1500 µg/ml 
C 325 µl 325 µl of Stock 1000 µg/ml 
D 175 µl 175 µl of vial B dilution 750 µg/ml 
E 325 µl 325 µl of vial C dilution 500 µg/ml 
F 325 µl 325 µl of vial E dilution 250 µg/ml 
G 325 µl 325 µl of vial F dilution 125 µg/ml 
H 400 µl 100 µl of vial G dilution 25 µg/ml 
I 400 µl 0 0 
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ii. WR was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA 
Reagent B (50:1, Reagent A: B). For the above example, 50 ml of Reagent A 
was combined with 1 ml of Reagent B. 
Note: When Reagent B is first added to Reagent A, turbidity is observed that quickly 
disappears upon mixing to yield a clear, green WR. The sufficient volume of WR was 
prepared based on the number of samples to be assayed. The WR is stable for several 
days when stored in a closed container at room temperature (RT). 
c. Microplate Procedure (Sample to WR ratio = 1.8) 
i. 25 μl of each standard or unknown sample replicate was pippete out into a 
microplate well (working range 20-2000 μg/ml).  
Note: If sample size is limited, 10 μl of each unknown sample and standard can be used 
(sample to WR ratio 1: 20). However, the working range of the assay in this case will be 
limited to 125-200 μg/ml.  
ii. 200 µl of the WR was added to each well and a plate mixed thoroughly on a 
plate shaker for 30 seconds. 
iii. The plate was covered and incubated at 37°C for 30 minutes. 
iv. The plate was cooled to RT. 
v. The absorbance was measured at 562 nm on a plate reader. 
Notes: 
Wavelengths from 540-590 nm have been used successfully with this method. Because 
plate readers use a shorter light path length than cuvette spectrophotometers, the 
Microplate Procedure requires a greater sample to WR ration to obtain the same 
sensitivity as the standard Test Tube Procedure. If higher 562 nm measurements are 
desired, increase time to 2 hours.  
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Increasing the incubation time or ratio of sample volume to WR increases the net 562 
nm measurement for each well and lowers both the minimum detection level of the 
reagent and the working range of the assay. As long as all standards and unknowns are 
treated identically, such modifications may be useful.  
vi. The average 562 nm absorbance measurement of the Blank standard replicates 
was subtracted from the 562 nm measurements of all other individual standard 
and unknown sample replicates. 
vii. A standard curve was prepared by plotting the average Blank-corrected 562 nm 
measurement for each BSA standard versus its concentration in µg/ml. The 
standard curve was used to determine the protein concentration of each unknown 
sample. 
Note: If using curve-fitting algorithms associated with a microplate reader, a four-
parameter (quadratic) or best-fit curve will provide more accurate results than a purely 
linear fit. If plotting results by hand, a point-to-point curve is preferable to a linear fit to 
the standard points. 
1.2 Preparation of Reagents for Anti-diabetic Inhibitory Assays 
1.2.1 Preparation of Reagents for Alpha Glucosidase Inhibitory Assay  
a. Preparation of 1.0 M Potassium Phosphate Buffer, pH 6.9 
 3.722 g of potassium dihydrogen phosphate (KH2PO4) and 3.713 g of 
dipotassium hydrogen phosphate (K2HPO4) were weighed and dissolved in 400 ml of 
distilled water. The solution was mixed well in a beaker using a magnetic stirrer. The 
solution was adjusted to pH 6.9 by adding either K2HPO4 as base or KH2PO4 as acid. 
Then the sodium phosphate buffer as topped up to 500 ml with distilled water in a 
volumetric flask. The solution was kept at RT. 
b. Preparation of 3mM p-nitrophenyl-𝛂-D-glucopyranoside, pH 6.9 
0.045 g of p-nitrophenyl-α-D-glucopyranoside (pNPG) (Sigma Aldrich) was 
weighed and dissolved in 50 ml of 1.0 M phosphate buffer, pH 6.9. Since the chemical 
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is sensitive to light, the solution preparation was carried out in the dark condition and 
stored in an aluminium foil wrapped bottle. The solution was prepared freshly upon 
usage and kept in an ice bath. 
c. Preparation of 0.1 M Sodium Carbonate (Na2CO3) Solution 
5.30 g of sodium carbonate (Na2CO3) was weighed and dissolved in 500 ml 
distilled water and kept at room temperature. 
d. Preparation of Saccharomyces cerevisiae Alpha Glucosidase Enzyme 
 Alpha glucosidase enzyme from Saccharomyces cerevisiae (Type I) was 
purchased from Sigma Aldrich Co., which in lyophilized powder. For a stock solution 
(1 U/ml), Saccharomyces cerevisiae alpha glucosidase (100 U) was dissolved in 100 ml 
of pre-chilled sodium phosphate buffer, pH 6.9. The enzyme was then aliquot into 1 ml 
in each in eppendorf tubes that has been fully covered with aluminium foils. The 
enzyme solution was stored at -20°C freezer for further use. According to the 
manufacturer’s product description, one unit will liberate 1.0 μmole of D-glucose from 
p-nitrophenyl-𝛼 -D-glucoside per min at pH 6.8 at 37°C. 
 For Saccharomyces cerevisiae alpha glucosidase inhibitory assay, 1 ml from 
stock solution of alpha glucosidase enzyme was dissolved in 9 ml of 1.0 M sodium 
phosphate buffer, pH 6.9. The solution was placed in an ice bath during the experiment 
and prepared freshly prior to assay. For storage, the Saccharomyces cerevisiae alpha 
glucosidase enzyme solution was stored at -80°C prior to assay. [Note: The S.   
cerevisiae alpha glucosidase enzyme was sensitive and unstable, therefore, freeze and 
re-thaw is not preferable]. 
e. Preparation of Voglibose  
Voglibose was used as a positive control for alpha glucosidase inhibitory assay. 
It was purchased from Sigma Aldrich Co. in lyophilized form. According to 
manufacturer’s product description, it was a modified tetrasaccharide that acts as a 
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reversible alpha glucosidase inhibitor. Stock solution (1 mg/ml) was prepared by 
dissolving 10 mg of enzyme powder in 10 ml in distilled water.  
The stock solution was then diluted to a concentration that was required for 
Saccharomyces cerevisiae alpha glucosidase inhibitory assay which was 25 µg/ml for 
voglibose and protein fraction, while for crude sample extracts was 25 mg/ml. The stock 
solution was stored at -20°C refrigerator for further use.  
1.2.2 Preparation or Reagent for Amylase inhibitory Assay 
a. 0.02 M Sodium Phosphate buffer, 0.006 M sodium chloride, pH 6.9 
For sodium phosphate buffer, the following two solutions were prepared separately: 
• Solution of 0.2 M Sodium dihydrogen phosphate dehydrate (NaH2PO4.2H2O) was 
prepared by dissolving 15.6 g NaH2PO4.2H2O with 500 ml dH2O. 
• Solution of 0.2 M Disodium hydrogen phosphate heptahydrate, (Na2HPO4.7H2O) 
was prepared by dissolving 53.65 g Na2HPO4.7H2O with 1 L dH2O.  
Firstly 0.1 M sodium phosphate buffer was prepared by adding 135 ml of 0.2 M 
NaH2PO4.2H2O solution and 165 ml of 0.2 M Na2HPO4.7H2O solution. The mixture 
was mixed well using a stirrer followed by addition of distilled water until reached 600 
ml. The solution was adjusted to pH 6.9 by adding either Na2HPO4 as base and 
NaH2PO4 as acid.  
For final concentration 0.02 M sodium phosphate buffer 0.006 M sodium 
chloride pH 6.9, a dilution has been made by pipetted out 200 ml from stock of 0.1 M 
sodium phosphate buffer and topped up until 1000 ml with distilled water in volumetric 
flask. Finally 0.3506 g of sodium chloride (NaCl) was added and pH was adjusted to pH 
6.9. 
b. Starch (0.5 %) 
 Soluble starch from potato (0.5 g), which purchased from Sigma Aldrich Co. 
was dissolved in 100 ml of 0.02 M Sodium Phosphate buffer, 0.006 M sodium chloride, 
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pH 6.9. Constant stirring at 90°C during the assay period helped the dissolution of 
starch in buffer. The starch solution was then cooled at room temperature. The starch 
solution prepared freshly prior to assay. 
c. Preparation of Dinitrosalicylic Acid (DNS) solution. (1 % (w/v) DNS, 12 % (w/v) 
sodium potassium tartrate in 0.4 M sodium hydroxide). 
 300 ml of distilled water was filled in aluminium foil covered bottle and placed 
on a hot plate with a stirrer. Lyophilized 3-5 dinitrosalicylic acid (DNS) (3 g) were 
added with continuous stirring. Then, 4.8 g of sodium hydroxide was added gradually 
until completely dissolve. 36 g of sodium potassium tartrate were the added very slowly 
over 20-30 minutes period, with constant stirring. The mixture was left at room 
temperature. This preparation was done in a dark room. 
d. Preparation of Alpha Amylase Enzyme 
Alpha amylase from porcine pancreas was purchased from Sigma Aldrich Co. in 
lyophilized form (Type VI-B). According to the manufacturer’s product description, 
one unit of enzyme will liberate 1.0 mg of maltose from starch in 3 minutes at pH 6.9, 
20°C. Stock solution (1 mg/ml) was prepared by dissolving 100 mg of enzyme powder 
in 100 ml pre-chilled sodium phosphate buffer pH 6.9. The enzyme was then aliquot 
into 10 ml each in plastic centrifuge tubes, which has been fully covered with 
aluminium foil. For alpha amylase inhibitory assay, the stock solution was diluted to 0.5 
mg/ml using the same buffer solution. The solution was placed in the ice bath during the 
experiment and prepared freshly prior to assay. For storage, the enzyme solution was 
stored at temperature -20°C prior to assay. [Note: The enzyme was sensitive and 
unstable furthermore need re-thaw is not preferable]. 
e. Preparation of Acarbose   
Acarbose (G5003) was used as a positive control for alpha amylase inhibitory 
assay (Sigma Aldrich Co.), which in lyophilized form. For stock solution, 10 mg/ml of 
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acarbose was prepared. The stock solution was then diluted to a concentration that was 
required for alpha amylase inhibitory assay for acarbose and protein fraction, which 
were 25 μg/ml, while for crude sample extracts was 25 mg/ml. The stock solution was 
stored at -20°C refrigerator for further use. 
1.3 Preparation of stock solutions for glycine SDS-PAGE system 
a. Solution A: Monomer acrylamide and bisacrylamide (30.8 % T, 2.7 % Cbis) 
 30 g of acrylamide and 0.8 g of N, N’-Methylenebisacrylamide were weighted 
and dissolved in distilled water. The mixture left with stirring and after dissolved, 
topped up with distilled water to 100 ml. The solution was deionised using a small 
quantity of Amberlite IRN-150L and continued stirred for 1 hour. Amberlite IRN-150L 
is a homogenous mixture of strong cationic and strong anionic resins. It is used to 
remove trace ionic impurities from non-ionic acrylamide solution. The amberlite IRN-
150L was then removed from the mixture by filtered and stored up to 3 months in a dark 
bottle. The solution was kept at 4°C. 
b. Solution B: 4x running gel buffer (1.5 M Tris- HCl pH 8.8) 
 18.7 g of Tris base was weighted and dissolved then made up to 100 ml with 
distilled water. The pH was then adjusted to pH 8.8 using concentrated hydrochloric 
acid (HCl). The solution was kept at 4°C freezer. 
c. Solution C: (10 % (w/v) SDS) 
 10 g of Sodium Dodecyl Sulfate (SDS) was dissolved and made up to 100 ml 
with distilled water. The solution was stored at room temperature. 
d. TEMED (N, N, N, N’- Tetramethyl ethylenediamine) 
 TEMED was purchased from Sigma Aldrich Chemical Co. The reagent was 
directly used and needed to be stored at room temperature.  
e. 10 % APS (10 % (w/v) ammonium persulphate)  
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 10 g of APS was dissolved and made up to 100 ml with distilled water. The 
solution was prepared prior to use or prepared earlier and stored in aliquots. The 
solution was kept at -20°C freezer. 
f. Solution D: Stacking gel buffer (0.5 M Tris – HCl, pH 6.8) 
 6.06 g of Tris base was dissolved and made up to 100 ml with distilled water. 
The pH was then adjusted to pH 6.8 using concentrated HCl. The solution was kept at 
4°C freezer. 
g. 4x SDS-PAGE sample buffer (0.1 % (w/v) Bromophenol Blue, 10 % (w/v) 
Glycerol, 2 % (w/v) SDS, 1 % (w/v) DTT 62.5 mM Tris – HCl pH 6.8) 
 
 Bromophenol blue (20 mg), 2.0 ml of Glycerol, 400 mg of SDS and 200 mg of 
DTT (dithiothreitol) were mixed together. Then 2.5 ml of solution D was added and 
made up to 20 ml with ddH2O. The buffer was stored at -20°C in aliquots for further 
use. 
h. Tank buffer or cathode buffer (25 mM Tris, 198 mM glycine, 0.1 % (w/v) SDS, 
pH 8.3) 
 
 3.03 g Tris base, 14.4 g Glycine and 1.0 g SDS were mixed and made up to 1 
litre with distilled water. The solution was kept at room temperature. The buffer can be 
reused but make sure it was filtered and not contaminated. 
1.4 Preparation of SDS-PAGE gels 
1.4.1 Recipe for the preparation of separating gel with final concentration 16 % 
 
 
 
 
 
 
This recipe was used to prepare 0.75 mm thick gel. Final volume of (20ml) is enough to 
prepare 2 gels. *10 % APS and TEMED were freshly prepared and added prior to 
pouring into gel-casting apparatus. 
Running gel final 
concentration 
Volume for 16 % acrylamide gels 
Solution A 10 680 μl 
Solution B 5000 μl 
Solution C 200 μl 
Distilled water 4020 μl 
* TEMED 6.6 μl 
* 10 % APS 100 μl 
Total Volume 20 ml 
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1.4.2 Recipe for the preparation of stacking gel which final concentration 4 % 
 
 
 
 
  
 
This recipe was used to prepare 0.75 mm thick gel. Final volume of (5 ml) is enough to 
prepare 2 gels.*10 % APS and TEMED were freshly prepared and added prior to 
pouring into gel-casting apparatus 
 
 
1.5 Preparation of Stock Solution of Coomassie Staining: 
a. Staining solution (0.1 % Coomassie Brilliant Blue R-250 in 10 % acetic acid 
and 40 % methanol) 
 1.0 g of Coomassie Brilliant Blue R-250 was added to 400 ml of methanol and 
stirred until dissolved. Then 100 ml of acetic acid were mixed and made up to 1 liter 
with distilled water. Filtering was not required. The solution was stored in a dark place. 
b. De-staining solution (10 % Acetic acid) 
 100 ml of acetic acid was added to 900 ml of distilled water. The solution was 
kept at room temperature.  
1.6 Preparation of Mobile Phase for High Performance Liquid Chromatograph 
(HPLC):  
a. Preparation of pump A solution: 0.1 % Trifluoroacetic acid (TFA) 
 For preparation of 1 L the solution, 1 ml of Trifluoroacetic acid (TFA) HPLC 
grade was purchased from Fisher Scientific was added to 999 ml of distilled water. The 
solution mixed using a magnetic stirrer. Before use, the solution was filtered with 
Whatman cellulose filter membrane by using vacuum pump. 
b. Preparation of pump B solution: 100 % Acetonitrile (ACN) 
Running gel final 
concentration Volume for 4 % acrylamide gels 
Solution A 650 μl 
Solution D 1250 μl 
Solution C 50 μl 
Distilled water 3050 μl 
* TEMED 5 μl 
* 10 % APS 25 μl 
Total 5.3 ml 
 131 
 Acetonitrile (ACN) HPLC grade were purchased from Fisher Scientific. 1 L of 
ACN was measured and filtered using Whatman nylon membrane filter paper. 
c. Methanol 
 Methanol with HPLC grade were purchased from Fisher Scientific was 
measured to 100 ml, transferred to a Schott Duran bottle and then furthered to a 
filtration by using Whatman nylon filter. 
1.7 Method Development of High Performance Liquid Chromatogram (HPLC) 
 The mobile phase consisted of two solvent system; pump A- (0.1 % (v/v) 
trifluoroacetic acid (TFA) in water and pump B- (100 % acetonitrile). Prior to 
chromatography, the instrument with a column needs to be flushed with 95 % 
acetonitrile for 30 minutes at flow rate of 0.9 mL/min in isocratic flow. Then the 
column was flushed with 0 % of acetonitrile in pump B for 10 minutes. The filtered 
methanol was injected to the injector to rinse the loop for several times for contaminants 
removal. 
 For the baseline, the system was run at 0-90 % acetonitrile (pump B) for 40 
minutes with binary gradient flow. The mobile phase solution was allowed to pass 
through the HPLC column until a stable baseline signal was equilibrated. After 
optimization, the system was set as A: 0.1 % trifluoroacetic acid (TFA) in water (v/v) 
and B: 100 % acetonitrile in a gradient (40 min, 0-95 % pump B) by binary gradient 
mobile composition. 
 For analytical run, the injection volume was 20 μl with 2 mg/ml concentration 
and the wavelength was monitored at 220 nm and 254 nm. All the systems, temperature 
and sample ID were set prior to the HPLC run. 
 The syringe filter was rinsed with 2-3 ml aliquots of  methanol between each 
use. Sample was dissolved in distilled water and filtered with 13 mm, 0.45 μm syringe 
filter prior to chromatography. The manual injector was switched the to the “load” 
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position at least three 20 μl volumes of each sample were pushed through the loop, 
making certain each volume does not contain air bubbles. 
 With the syringe still in the injector, the knob was turned to the “inject” position, 
at which the instrument will automatically start data acquisition. The injector was left in 
the “inject” position, and the syringe was removed after 5 minutes. The column 
temperature was kept at 40°C and the flow rate were set at 1.0 mL/min.  
 For sample collection, the column was changed with semi preparative column 
and the concentration also remains as 2 mg/ml. The HPLC system was maintained. 
Methanol was used as to rinse a syringe and a loop with at least 3 volumes of the 
methanol and later dispensed into the waste beaker. At the end of the day of multiple 
runs, the column was washed for 30 minutes with 100 % acetonitrile to remove 
unbound components. 
1.8 Preparation of Stock solutions for Silver Staining Protocols (MS Compatible) 
a. Fixing solution (40 % (v/v) ethanol, 10 % (v/v) glacial acetic acid) 
 400 ml of ethanol and 100 ml of glacial acetic acid were mixed and made up to 1 
litre with distilled water. The solution was kept in room temperature. The solution was 
freshly prepared before use. 
b. Incubation/Sensitizing solution (30 % (v/v) ethanol, 6.8 % (w/v) sodium 
acetate, 0.2 % sodium thiosulfate) 
 
 300 ml of ethanol, 68 g of sodium acetate and 2 g of sodium thiosulphate* were 
mixed and made up to 1 litre with distilled water. The solution must be freshly prepared 
before use. 
c. Silver solution (0.5 % (w/v) silver nitrate) 
 1 g of silver nitrate were mixed with 1 litre distilled water. The solution must be 
freshly prepared before use. 
d. Developing solution (0.24 M sodium carbonate, 0.02 % (v/v) formaldehyde) 
 133 
 25 g of sodium carbonate and 100 μl of formaldehyde* were mixed and made up 
to 1 litre with distilled water. The solution must be freshly prepared before use. 
e. Stop solution (400 mM EDTA-Na2.2H2O) 
 14.6 g of EDTA-Na2.2H2O were made up to 1 litre with distilled water. The 
solution was kept at room temperature. 
* The material was added freshly prior to use 
 
1.9 Preparation of Reagents Matrix-Assisted Laser Desorption/Ionization 
(MALDI) for In-Solution Digestion Protocol.  
a. Digestion buffer (50 mM Ammonium bicarbonate) 
 10 mg of ammonium bicarbonate was weighed and dissolved in 2.5 ml of 
ddH2O for a final concentration of ~50 mM. This solution can be stored at 4°C for up to 
two months. 
b. Reducing solution (100 mM Dithiothreitol (DTT) 
 8 mg of DTT as weighed and dissolved with 500 μl of ddH2O for a final 
concentration ~100 mM. Reducing solution can be stored at -20 °C. 
c. Alkylation solution 
 Alkylation solution was freshly prepared just before use. Iodoacetamide (IAA) 
(9 mg) was weighed and added to a foil-wrapped tube to avoid exposure of light. 
DdH2O (500 μl) was added for a final concentration of ~100 mM. Excess solution 
cannot be stored.  
d. Trypsin stock 
 Trypsin stock solution was prepared at concentration of 0.1 µg/ml .  Two 
hundred µl of trypsin suspension buffer was added to 20 µg of trypsin. This solution 
was stored at -20°C for up to two months. 
e. Protein concentrations 
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 The procedure described was been found to work well with protein 
concentrations in the range 0.1-1.0 mg/ml. This concentration range allowed working 
with protein from 0.1 µg to 10 µg, respectively in 10 µl total volume for the digestions. 
 
1.10 Preparation of Reagents and Procedure for Matrix-Assisted Laser 
Desorption/Ionization (MALDI) for In-Gel Digestion Protocol 
 
a) Stock materials in the set 
Stock materials Label Storage 
Potassium ferricyanide K3Fe (CN)6 PF Room temperature, in dark 
Sodium thiosulfate ST Room temperature, in dark 
50 mM Ammonium bicarbonate 
NH4HCO3 
50 AB Room temperature 
10 mM Ammonium bicarbonate 
NH4HCO3 
10 AB Room temperature 
Acetonitrile (HPLC grade) 100 % ACN Room temperature, in dark 
50 % Acetonitrile (HPLC grade) 50 % ACN Room temperature, in dark 
5 % Formic acid/ 50 % Acetonitrile 5 % FA / 50 
% ACN 
Room temperature, in dark 
0.1 % Formic acid/ 50 % Acetonitrile 0.1 % FA / 50 
% ACN 
Room temperature, in dark 
0.1 % Formic acid 0.1 % FA Room temperature, in dark 
Menthol (HPLC grade) MeOH Room temperature, in dark 
100 mM Dithiothreitol 100mM DTT -20ºC 
Iodoacetamide IAA 4ºC 
Trypsin (Stock) Trypsin -20ºC 
ZipTip uC-18 (10 µL)  Room temperature 
 
b) Solutions prepared prior use 
Chemicals Preparation 
30 mM Potassium 
ferricyanide K3Fe (CN)6 
2 ml MilliQ water was added to the tube (can be 
stored at 4ºC for a few days) 
100 mM Sodium 
thiosulfate 
2 ml MilliQ water was added to the tube (can be 
stored at 4ºC for a few days) 
Silver Destaining 
solution 
“PF” and “ST” were mixed in 1:1 ratio 
(Note: This solution must be freshly prepared prior 
use, and cannot be re-used) 
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c) Procedure 
A. Gel piece destaining and washing: 
 (1) Destainingvof silver stained gel 
1. Gel band or spot was cut into smaller pieces. 
2. Gel pieces was covered with ~150-200 µl de-staining solution, incubated at room 
temperature 15 min or until brownish colour was removed. Further to short spun, and 
the solution were removed. The gel was washed briefly with 300 µl MilliQ and the 
solution was removed. 
3. The gel pieces were washed with 300 µl MilliQ for 10 min, to remove de-staining 
solution residual. The procedure was repeated. 
4. The gel pieces were washed with 200 µl 50 % ACN for 15 min and the  solution was 
removed. The procedure was repeated. 
5. The gel was shrank by adding 150 µl 100 % ACN and briefly vortexed. The solution 
was removed. 
6. Gel was re-hydrated in 50 µl 10 mM NH4HCO3 for 5-10 min. The solution was 
removed. 
7. The gel was shrank by adding ~150-200 µl of 100 % ACN 5-10 min. Further to short 
spin and the solution was removed. 
8. The shrank gel was dried in Speed Vac. for 5 min at < 30ºC. (Gel can be stored  at 
20ºC if required). 
10 mM Dithiothreitol 
DTT 
100 mM DTT was diluted 10 times using 10 mM 
Ammonium bicarbonate 
(Note: This solution must be freshly prepared prior 
use, and cannot be re-used) 
55 mM Iodoacetamide 
IAA 
1 ml 10 mM NH4HCO3 was added to the tube 
(Note: This solution must be freshly prepared prior 
use, and cannot be re-used) 
Trypsin working solution 
12.5 ng/ µl 
1 µl stock solution + 79 µL 10 mM NH4HCO3 
(Note: This solution must be freshly prepared prior 
use, and cannot be re-used) 
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(2) Reduction and Alkylation for 1-D gel 
1. 50 µl or sufficient amount of freshly prepared 10 mM DTT/ 10 mM NH4HCO3 was 
added to cover gel pieces and incubated at 56ºC for 40-60 min. 
2. The tubes were chilled to RT. Further to short spin and DTT solution was removed. 
3. The same volume of freshly prepared 55 mM IAA / 10 mM NH4HCO3 were 
added. Incubated at room temp (in DARK) for 30-45 min. 
4. Further to short spin and IAA solution was removed at once. 
5. 300 µl MilliQ was used to wash gel for 10 min. The solution was removed and the 
procedure was repeated. 
6. 200 µl 50 % ACN was added to wash gel for 15 min. The solution was removed and 
the procedure was repeated. 
7. 150 µl 100 % ACN was added to shrink the gel, and the tube was briefly vortexed. 
The solution was removed. 
8. The gel was re-hydrated in 50 µl 10 mM NH4HCO3 for 5-10 min. 
9. 50 µl 100 % ACN was added to further equilibrate gel for 15 min more. Short spin 
and the solution were removed. 
10. The gel was shrank by adding ~150-200 µl ACN. Short spin and the solution was 
removed.  
11. The shrunk gel was dried in Speed Vac. for 10-15 min at < 30ºC. 
B. In Gel-digestion: 
1. 15-20 µl (depends on gel size, volume that adequate to cover the gel piece) of 12.5 
ng/µl trypsin working solution was added to samples, or add until gel pieces are covered 
by the trypsin working solution. 
2. The samples were pre-incubated for 30-40 min at 4ºC to ensure complete re-swelling 
of gel pieces. If the gel pieces appear white or opaque after pre-incubation, additional 
10 µl was added and incubated for another 30 min. 
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3. The remaining trypsin supernatant was removed and 15-20 µl (depends on gel size, 
volume that adequate to cover the gel piece) of ice-cold 10 mM NH4HCO3 was added to 
keep the gel wet during the enzymatic cleavage. 
4. The gel was incubated for 14-16 hours at 37ºC. 
C. Peptides Extraction: 
1. The sample tubes/ plate has been a short spun. 
2. The solution was extracted in a new tube (extracts). 
3. The gel was extracted again by adding 20 µl 5 % formic acid: 50 % ACN (= 1:1 
volume of 10 % formic acid + 100 % ACN), vortex or mixing in the shaker for 15 min. 
the removed solution were all recovered in the extracts tube. The procedure was 
repeated once. 
4. The gel was extracted again with 20 µl 100 % ACN. 
5. The solution was recovered in the extracts tube. 
6. The solution was concentrated to ~10-20 µl, in Speed Vac for ~ 1 to 1.5 hour at  room 
temp (*do not > 30ºC). The solution was prevented from totally dried out.  If the 
solution dried out, recovered peptides by adding ~ 15 µl 0.1 % FA with sonication for 1 
min. 
7. The recovered peptides are ready for further processing or store < -20°C. 
D. Zip Tip Protocol 
1. The tip was wet by with 10 µl 50 % ACN /0.1 % FA for 5 times. 
2. The tip was washed again with 10 µl of 0.1 % FA for 5 times. 
3. The sample was filled into tip by pipetting fully into and out of tip >30 times. The 
liquid was expelled. 
4. The tip was washed with 10 µl 0.1 % FA to remove contaminants for 3 times. 
5. The peptides was eluted in 4 µl 50 % ACN /0.1 % FA by pipetting fully  into and out 
of tip >30 times in new tube. 
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6. The eluted peptides can be stored < -20°C for further use. 
Note: During the Zip-Tip procedure, please be careful and do not introduce any air 
bubbles as this may block the c18 mini-column at the tip-end.  
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1.0 In-vitro Screening of Solvent Extracts and Protein Fractions from P. 
pulmonarius Basidiocarps for Anti-diabetic Enzymes Inhibitory Assays 
 
Table 1.1: In-vitro Screening for Saccharomyces cerevisiae Alpha Glucosidase 
Inhibitory Activity Assay     
a) Crude extracts at 25 mg/ml concentration 
 
Samples 
 
Replicates Average Percentage of 
inhibition (%) 1 2 3 
Voglibose  1.329 1.44 1.433 1.4 5.23 
Crude aqueous 
extract  
0.457 0.524 0.427 0.46 73.50 
Polysaccharide 
extract 
0.256 0.27 0.274 0.277 85.82 
Methanol extract 1.752 1.693 1.668 1.70 2.61 
Dichloromethane 
extract 
0.158 0.142 0.2 0.17 91.13 
 
 
 
 
b) Protein fractions at 25 μg/ml concentration 
 
Samples  Replicates Average Percentage of inhibition 
(%) 1 2 3 
Voglibose 1.329 1.64 1.433 1.47 5 
F10 1.85 1.896 1.81 1.85 1 
F20 2.223 2.087 2.16 2.16 0 
F30 1.45 1.505 1.346 1.43 24 
F40 1.801 1.712 1.758 1.76 7 
F50 1.604 1.797 1.876 1.76 6 
F60 1.578 1.446 1.5 1.51 20 
F70 1.856 1.675 1.723 1.75 7 
F80 1.576 1.55 1.547 1.56 17 
F90 1.58 1.588 1.577 1.58 16 
F100 1.936 1.95 1.959 1.95 0 
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Table 1.2: In-vitro Screening for Porcine Pancreatic Alpha Amylase Inhibitory Activity 
Assay 
 
a) Crude extracts at 25 mg/ml concentration 
Samples 
 
Replicates Average Percentage of inhibition 
(%) 1 2 3 
Acarbose 0.321 0.351 0.336 0.336 20.90 
Crude aqueous 
extract 0.186 0.244 0.265 0.23 87.74 
Polysaccharide 
extract 0.967 1.014 0.962 0.98 48.10 
Methanol extract 1.066 1.089 1.092 1.08 42.73 
Dichloromethane 
exract 1.336 1.311 1.332 1.33 29.82 
 
 
 
 
b) Protein fractions at 25 μg/ml concentration 
Samples  Replicates Average Percentage of inhibition (%) 
1 2 3 
Acarbose 0.321 0.351 0.336 0.336 20.9 
F10 0.377 0.377 0.392 0.382 10.1 
F20 0.35 0.379 0.37 0.366 13.8 
F30 0.39 0.376 0.396 0.387 8.9 
F40 0.397 0.381 0.367 0.381 10.4 
F50 0.376 0.364 0.321 0.357 16.0 
F60 0.351 0.341 0.344 0.345 18.7 
F70 0.292 0.271 0.317 0.293 31.0 
F80 0.393 0.415 0.303 0.370 12.9 
F90 0.339 0.355 0.327 0.302 29.0 
F100 0.221 0.256 0.265 0.247 41.8 
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2.0 Bioassay-guided Purification of Selected Active (NH4)2SO4 Protein Fractions 
by Reverse Phase High Performance Liquid Chromatography (RP-HPLC) 
 
Table 2.1: Alpha glucosidase inhibitory assay of fractionated protein fractions 
 
Samples 
(Protein 
fraction) 
Replicates Average Percentage of inhibition 
(%) 
1 2 3 
Voglibose 1.567 1.72 1.799 1.70 13 
Peak 1 1.548 1.758 1.575 1.63 17 
Peak 2 1.715 1.386 1.673 1.59 18 
Peak 3 1.5 1.4 1.46 1.46 25 
Peak 4 1.557 1.537 1.447 1.51 22 
Peak 5 1.441 1.61 1.806 1.62 17 
Peak 6 1.577 1.53 1.623 1.58 19 
Peak 7 1.632 1.656 1.731 1.67 14 
Peak 8 1.602 1.552 1.382 1.51 22 
Peak 9 1.51 1.651 1.61 1.59 18 
Peak 10 1.625 1.555 1.67 1.62 17 
 
 
 
 
 
 
Table 2.2: Alpha amylase inhibitory assay of fractionated protein fractions 
 
Samples 
(Protein 
fraction) 
Replicates Average Percentage of inhibition 
(%) 
1 2 3 
Acarbose 1.941 1.931 1.905 1.926 2.051542896 
Peak 1 1.905 2.016 1.984 1.968 0 
Peak 2 2.081 2.005 1.969 2.018 0 
Peak 3 1.864 1.95 1.916 1.910 2.848423194 
Peak 4 1.94 1.945 1.95 1.945 1.068158698 
Peak 5 1.909 1.95 1.954 1.938 1.441166497 
Peak 6 1.959 1.964 1.969 1.964 0.1017294 
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APPENDIX C: ONE-WAY ANOVA analysis 
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1.0  In-vitro Screening of Solvent Extracts and Protein Fractions from P. 
pulmonarius Basidiocarps for Anti-diabetic Enzymes Inhibitory Assays  
 
1.1. In-vitro Screening for Saccharomyces cerevisiae Alpha Glucosidase Inhibitory 
Activity Assay 
 
1.1.1. The statistical data of one-way ANOVA on percentage inhibition of 
Saccharomyces cerevisiae alpha glucosidase assay activity by aqueous, 
polysaccharide, methanol and dichloromethane extracts at 25 mg/ml. 
 
 
Level indicates 
1:  voglibose  
2:  aqueous extracts 
3:  polysaccharide extracts 
4:  methanol extracts 
5:  dicholoromethane extracts 
  
 
 
 
 
 
 
One-way ANOVA: Percentage of inhibition versus crude extracts (mg/ml) 
       
Source  DF       SS       MS       F      P     
C1       4  5.92051  1.48013  806.37  0.000    
Error   10  0.01836  0.00184     
Total   14  5.93887     
S = 0.04284   R-Sq = 99.69 %   R-Sq(adj) = 99.57 %  
   
Individual 95 % CIs For Mean Based on Pooled StDev    
Level  N    Mean   StDev  --------+---------+---------+---------+-  
  
1      3  1.4007  0.0622                           (*)   
  
2      3  0.4693  0.0497        (*)     
3      3  0.2667  0.0095    (*)     
4      3  1.7043  0.0431                                 (*)  
  
5      3  0.1667  0.0300  (*)     
--------+---------+---------+---------+-     
0.50      1.00      1.50      2.00  
    
Pooled StDev = 0.0428 
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1.1.2. The statistical data of one-way ANOVA on percentage inhibition of 
Saccharomyces cerevisiae alpha glucosidase activity assay by (NH4)2SO4 
protein fractions (F10-100) samples and voglibose at 25 µg/ml protein 
concentration 
 
 
Level indicates 
1:  voglibose  
2:  F10  
3:  F20  
4:  F30  
5:  F40  
6:  F50  
7: F60  
8:  F70 
9:  F80 
10: F90 
11:  F100  
  
  
One-way ANOVA: Percentage of inhibition versus protein fractions (mg/ml) 
      
Source  DF      SS     MS      F      P     
C1      10  2034.0  203.4  12.55  0.000     
Error   22   356.6   16.2     
Total   32  2390.6        
S = 4.026   R-Sq = 85.08 %   R-Sq(adj) = 78.31 %    
  
Individual 95 % CIs For Mean Based on Pooled StDev     
Level  N    Mean  StDev  ------+---------+---------+---------+---  
   
 1     3  19.333  8.622                          (-----*-----)  
  
 2     3   0.167  0.289  (-----*-----)     
 3     3   0.000  0.000  (-----*-----)     
 4     3  21.000  4.583                            (-----*-----)  
  
 5     3   3.467  2.501      (-----*-----)     
 6     3   4.400  6.528       (------*-----)     
 7     3  17.333  4.041                        (-----*-----)  
  
 8     3   4.333  4.041       (-----*-----)     
 9     3  14.333  1.155                    (-----*-----)   
  
10     3  13.000  0.000                  (-----*-----)   
  
11     3   0.000  0.000  (-----*-----)     
                         ------+---------+---------+---------+---  
   
                             0.0       8.0      16.0      24.0  
    
Pooled StDev = 4.026  
 146 
1.2. In-vitro Screening for Porcine Pancreatic Alpha Amylase Inhibitory Activity 
Assay  
 
1.2.1. The statistical data of one-way ANOVA on percentage inhibition of porcine 
pancreatic alpha amylase activity by crude aqueous, polysaccharide, 
methanol and dichloromethane extracts at 25 mg/ml 
 
Level indicates 
1:  acarbose  
2:  aqueous extracts 
3:  polysaccharide extracts 
4:  methanol extracts 
5:  dicholoromethane extracts 
  
 
 
 
 
 
 
 
One-way ANOVA: Percentage of inhibition versus crude extracts (mg/ml) 
      
Source  DF       SS       MS       F      P     
C1       4  7365.04  1841.26  541.04  0.000     
Error   10    34.03     3.40     
Total   14  7399.07       
S = 1.845   R-Sq = 99.54 %   R-Sq(adj) = 99.36 %    
    
Individual 95 % CIs For Mean Based on Pooled StDev     
Level  N    Mean  StDev  ---------+---------+---------+---------+  
   
1      3  25.000  3.000  (*)     
2      3  87.767  2.178                                  (*)   
3      3  48.083  1.509              (*)     
4      3  42.733  0.757           (*)     
5      3  29.967  0.651     (*)     
                         ---------+---------+---------+---------+  
   
                                 40        60        80       100  
    
Pooled StDev = 1.845  
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1.2.2. The statistical data of one-way ANOVA on inhibition of porcine pancreatic 
alpha amylase activity by 10 %-100 % protein fractions and acarbose at 25 
µg/ml 
 
Level indicates 
1:  acarbose  
2:  F10  
3:  F20  
4:  F30  
5:  F40  
6:  F50  
7: F60  
8:  F70 
9:  F80 
10: F90 
11:  F100 
 
 
 
 
 
 
 
  
One-way ANOVA: Percentage of inhibition versus protein fractions (mg/ml) 
    
Source  DF      SS     MS     F      P     
C1      10  2789.4  278.9  9.46  0.000     
Error   22   648.7   29.5     
Total   32  3438.1         
S = 5.430   R-Sq = 81.13 %   R-Sq(adj) = 72.56 %     
Individual 95 % CIs For Mean Based on Pooled StDev     
Level  N    Mean   StDev  ----+---------+---------+---------+-----  
   
 1     3  25.000   3.000           (-----*----)     
 2     3  14.667   2.309   (----*-----)     
 3     3  18.000   3.606      (----*----)     
 4     3  13.333   2.517  (----*-----)     
 5     3  14.667   3.512   (----*-----)     
 6     3  21.000   6.245        (-----*----)     
 7     3  22.667   1.528         (-----*----)     
 8     3  35.000   5.000                    (----*-----)    
 9     3  17.000  13.229     (----*-----)     
10     3  24.000   3.000           (----*----)     
11     3  45.000   5.292                            (-----*----)  
   
                          ----+---------+---------+---------+-----  
   
                             12        24        36        48  
     
Pooled StDev = 5.430    
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1.3. Bioassay-guided Purification of Selected Active (NH4)2SO4 Protein Fractions 
by Reverse Phase High Performance Liquid Chromatography (RP-HPLC). 
 
1.3.1. The statistical data of one-way ANOVA on Alpha Glucosidase Inhibitory 
Assay of fractionated protein fraction  
 
Level indicates 
1:  voglibose  
2:  F10  
3:  F20 
4:  F30  
5:  F40  
6:  F50  
7: F60  
8:  F70 
9:  F80 
10: F90  
11:  F100  
 
 
 
 
  
One-way ANOVA: Percentage of inhibition versus protein fractions (mg/ml) 
 
Source  DF      SS     MS      F      P   
C1      10  849.32  84.93  26.52  0.000   
Error   22   70.46   3.20   
Total   32  919.78   
   
S = 1.790   R-Sq = 92.34 %   R-Sq(adj) = 88.86 %   
Individual 95 % CIs For Mean Based on Pooled StDev   
Level  N    Mean  StDev  -------+---------+---------+---------+--   
 1     3  10.000  2.000  (---*--)   
 2     3  20.200  0.721                   (---*--)   
 3     3  13.690  1.078        (---*--)   
 4     3  25.860  2.583                             (--*---)   
 5     3  22.777  2.984                       (---*---)   
 6     3  27.597  0.981                               (---*---)   
 7     3  19.547  2.350                  (---*--)   
 8     3  16.313  0.696             (--*---)   
 9     3  15.913  2.108            (---*--)   
10     3  22.267  1.184                       (--*---)   
11     3  15.897  1.076            (--*---)   
                         -------+---------+---------+---------+--   
                             12.0      18.0      24.0      30.0   
   
Pooled StDev = 1.790   
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1.3.2. The statistical data of one-way ANOVA on Alpha Amylase Inhibitory Assay 
of fractionated protein fraction  
 
Level indicates 
1:  acarbose  
2:  F10  
3:  F20  
4:  F30  
5:  F40  
6:  F50  
7: F60  
8:  F70 
9:  F80 
10: F90  
11:  F100  
  
One-way ANOVA: Percentage of inhibition versus protein fractions (mg/ml)  
   
Source  DF       SS      MS       F      P   
C1       6  5328.05  888.01  757.03  0.000   
Error   14    16.42    1.17   
Total   20  5344.48   
   
S = 1.083   R-Sq = 99.69 %   R-Sq(adj) = 99.56 %   
   
Individual 95 % CIs For Mean Based on Pooled StDev  
  
Level  N    Mean  StDev  -+---------+---------+---------+--------   
1      3   1.233  0.410   (*)   
2      3   2.180  1.888    *)   
3      3  46.567  2.043                                 (*)   
4      3   0.673  0.356   *)   
5      3   1.269  0.254   (*)   
6      3   0.790  0.225   (*   
7      3   0.301  0.250  (*)   
                         -+---------+---------+---------+--------   
                          0        15        30        45   
   
Pooled StDev = 1.083   
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APPENDIX D: MALDI-TOF/TOF MS ANALYSIS DATA  
 151 
1.0 MALDI-TOF/TOF MS Analysis of Five Protein Bands Obtained From Active Peak 3-RPF Silver-Stained Electrophoregram by In-Gel 
Digestion Protocol. 
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2.0 MALDI-TOF/TOF MS Analysis of Peak 3-RPF Protein by Using In-Solution 
Digestion Protocol. 
Mascot Search Results 
User            :  Email           :  Search title    : SampleSetID: 1461, AnalysisID: 3387, 
MaldiWellID: 135821, SpectrumID: 233890, Path=\071211\msms\azwa-re 
Database        : Sprot 080308 (261513 sequences; 95638062 residues) Timestamp       
: 19 Dec 2011 at 02:51:40 GMT Top Score       : 42 for PROF1_PHAVU, Profilin-1 
- Phaseolus vulgaris (Kidney bean) (French bean)  
 
Probability Based Mowse Score 
Ions score is -10*Log(P), where P is the probability that the observed match is a random 
event. 
Protein scores greater than 67 are significant (p<0.05). 
Top 
of Form 
Concise Protein Summary Report 
  Help  
  Significance threshold p<   Max. number of hits   
    
1.     PROF1_PHAVU       Mass: 14172    Score: 42     Expect: 19  Queries matched: 2 
  Profilin-1 - Phaseolus vulgaris (Kidney bean) (French bean) 
       PROF1_RICCO       Mass: 14199    Score: 42     Expect: 19  Queries matched: 2 
  Profilin-1 - Ricinus communis (Castor bean) 
       PROF1_SOYBN       Mass: 14091    Score: 42     Expect: 19  Queries matched: 2 
  Profilin-1 (GmPRO1) (Allergen Gly m 3.0101) - Glycine max (Soybean) 
       PROF2_HEVBR       Mass: 14142    Score: 42     Expect: 19  Queries matched: 2 
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  Profilin-2 (Pollen allergen Hev b 8.0102) - Hevea brasiliensis (Para rubber tree) 
       PROF2_MALDO       Mass: 14043    Score: 42     Expect: 19  Queries matched: 2 
  Profilin-2 (GD4-2) (Pollen allergen Mal d 4.0201) - Malus domestica (Apple) (Malus sylvestris) 
       PROF2_SOYBN       Mass: 14091    Score: 42     Expect: 19  Queries matched: 2 
  Profilin-2 (GmPRO2) (Allergen Gly m 3.0102) - Glycine max (Soybean) 
       PROF_FRAAN        Mass: 14058    Score: 42     Expect: 19  Queries matched: 2 
  Profilin (Allergen Fra a 4) - Fragaria ananassa (Strawberry) 
       PROF_PRUPE        Mass: 13980    Score: 42     Expect: 19  Queries matched: 2 
  Profilin (Allergen Pru p 4.02) - Prunus persica (Peach) 
 
2.   
  EX7S_GEOSL        Mass: 8693     Score: 38     Expect: 47  Queries matched: 2 
  Exodeoxyribonuclease 7 small subunit (EC 3.1.11.6) (Exodeoxyribonuclease VII small subunit) (Exonuc 
 
3.     Y1491_LACJO       Mass: 18213    Score: 37     Expect: 48  Queries matched: 2 
  UPF0090 protein LJ_1491 - Lactobacillus johnsonii 
 
4.   
  GPX3_CEBAP        Mass: 25517    Score: 37     Expect: 53  Queries matched: 2 
  Glutathione peroxidase 3 precursor (EC 1.11.1.9) (GSHPx-3) (GPx-3) (Plasma glutathione peroxidase)  
     
  GPX3_HUMAN        Mass: 25489    Score: 37     Expect: 53  Queries matched: 2 
  Glutathione peroxidase 3 precursor (EC 1.11.1.9) (GSHPx-3) (GPx-3) (Plasma glutathione peroxidase)  
     
  GPX3_MACFU        Mass: 25513    Score: 37     Expect: 53  Queries matched: 2 
  Glutathione peroxidase 3 precursor (EC 1.11.1.9) (GSHPx-3) (GPx-3) (Plasma glutathione peroxidase)  
     
  GPX3_PONPY        Mass: 25499    Score: 37     Expect: 53  Queries matched: 2 
  Glutathione peroxidase 3 precursor (EC 1.11.1.9) (GSHPx-3) (GPx-3) (Plasma glutathione peroxidase)  
     
  GPX3_HYLLA        Mass: 25535    Score: 37     Expect: 55  Queries matched: 2 
  Glutathione peroxidase 3 precursor (EC 1.11.1.9) (GSHPx-3) (GPx-3) (Plasma glutathione peroxidase)  
 
5.     Y012_METKA        Mass: 19878    Score: 36     Expect: 66  Queries matched: 2 
  UPF0254 protein MK0012 - Methanopyrus kandleri 
 
6.     Y362_HAEIN        Mass: 32443    Score: 35     Expect: 91  Queries matched: 2 
  Putative periplasmic iron-binding protein HI0362 precursor - Haemophilus influenzae 
 
7.     VG41_ICHV1        Mass: 33871    Score: 35     Expect: 91  Queries matched: 2 
  Hypothetical gene 41 protein - Ictalurid herpesvirus 1 (IcHV-1) (Channel catfish herpesvirus) 
 
8.   
  MYP0_HORSE        Mass: 27467    Score: 35     Expect: 91  Queries matched: 2 
  Myelin P0 protein precursor (Myelin protein zero) (Myelin peripheral protein) (MPP) - Equus 
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caballu 
       MYP0_RAT          Mass: 27553    Score: 35     Expect: 91  Queries matched: 2 
  Myelin P0 protein precursor (Myelin protein zero) (Myelin peripheral protein) (MPP) - Rattus norveg 
       MYP0_HUMAN        Mass: 27537    Score: 34     Expect: 1e+002  Queries matched: 2 
  Myelin P0 protein precursor (Myelin protein zero) (Myelin peripheral protein) (MPP) - Homo sapiens  
       MYP0_MOUSE        Mass: 27604    Score: 34     Expect: 1e+002  Queries matched: 2 
  Myelin P0 protein precursor (Myelin protein zero) (Myelin peripheral protein) (MPP) - Mus musculus  
       MYP0_BOVIN        Mass: 24695    Score: 34     Expect: 1.1e+002  Queries matched: 2 
  Myelin P0 protein (Myelin protein zero) (Myelin peripheral protein) (MPP) - Bos taurus (Bovine) 
 
9.   
  ISCU_HUMAN        Mass: 17926    Score: 34     Expect: 97  Queries matched: 2 
  Iron-sulfur cluster assembly enzyme ISCU, mitochondrial precursor (NifU-like N-terminal domain-cont 
 
10.    H2B1_WHEAT        Mass: 16423    Score: 34     Expect: 99  Queries matched: 2 
  Histone H2B.1 - Triticum aestivum (Wheat) 
 
Search Parameters 
Type of search         : Sequence Query Enzyme                 : Trypsin Variable 
modifications : Carbamidomethyl (C),Oxidation (M) Mass values            : 
MONOISOTOPIC Protein Mass           : Unrestricted Peptide Mass Tolerance : ± 
100 ppm Fragment Mass Tolerance: ± 0.2 Da Max Missed Cleavages   : 1 
Instrument type        : MALDI-TOF-TOF Query1 (842.57,1+)     :  MaldiWellID: 
135821, SpectrumID: 233898, Query2 (842.57,1+)     : <no title>  
Mascot:  http://www.matrixscience.com/  
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1.0 Proceedings for poster presented at the 5th International Peptide 
Symposium in conjunction with 47th Japanese Peptide Symposium. Date: 
December 4–9, 2010. Venue: Kyoto International Conference Center. Kyoto, 
Japan. 
 
 
 
 
